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Stroke is a highly heterogeneous and complex disease that is a leading cause of death in the
United States. The landscape of risk factors for stroke is vast, and its large genetic burden has yet
to be fully discovered. We hypothesize that the small number of stroke variants recovered so far is
due to 1) the vast phenotypic heterogeneity of stroke and 2) binary labeling of stroke
genome-wide association study (GWAS) participants as cases or controls. Specifically,
genome-wide association studies accumulate hundreds of thousands to millions of participants to
acquire adequate signal for variant discovery. This requires time-consuming manual curation of
cases and controls often involving large-scale collaborations. Genetic biobanks connected to
electronic health records (EHR) can facilitate these studies by using data routinely captured
during clinical care like billing diagnosis codes. These data, however, do not define adjudicated
cases and controls, with many patients falling somewhere in between. There is an opportunity to
use machine learning to add nuance to these definitions. We hypothesize that an expanded
definition of disease by incorporating correlated diseases and risk factors from EHR data will
improve GWAS power. We also hypothesize that granularly subtyping stroke using unsupervised
learning methods can provide insight into stroke etiology and heterogeneity. In Chapter 1, we
described the motivation for building upon current phenotyping methods for subtyping and
genome-wide association studies to improve GWAS power. In Chapter 2, using patients from
Columbia-New York Presbyterian (NYP) Hospital, we built and evaluated machine learning
models to identify patients with acute ischemic stroke based on 75 different case-control and
classifier combinations. In chapter 3, we compared two data-driven and unsupervised methods,
non-negative matrix factorization (NMF) and hierarchical poisson factorization, to subtype stroke
patients and determined whether any of the subtypes correlate to stroke severity. In chapter 4, we
estimated the heritability of acute ischemic stroke by treating the patient probabilities assigned by
the machine learning phenotyping models for acute ischemic stroke in chapter 2 as a quantitative
trait and mapping the probabilities to Columbia-NYP EHR-generated pedigrees. We also applied
our machine learning phenotyping algorithm method, which we call QTPhenProxy, to venous
thromboembolism on Columbia eMERGE Consortium patients and ran a genome-wide
association study using the model probabilities as a quantitative trait. Finally, we applied
QTPhenProxy to subjects in the UK Biobank for stroke and 14 other diseases and ran
genome-wide association studies for each disease. We found that our machine learned models
performed well in identifying acute ischemic stroke patients in the Columbia-NYP EHR and in
the UK Biobank. We also found some NMF-derived subtypes that were significantly correlated
with stroke severity. We were underpowered in the eMERGE venous thromboembolism cohort
GWAS and did not recover any known or new variants. Finally, we found that QTPhenProxy
improved the power of GWAS of stroke and several subtypes in the UK Biobank, recovered
known variants, and discovered a new variant that replicates in a previous stroke GWAS. Our
results for QTPhenProxy demonstrate the promise of incorporating large but messy sets of data,
such as the electronic health record, to improve signal in genome-wide association studies.
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Chapter 1: Introduction
Stroke is a leading cause of death and the top cause of disability in the US [1]. Almost 800,000
people in the United States have a stroke every year, and over one sixth of these result in death[2,
3]. In addition, the rate of decline of stroke death has decreased in recent years and even increased
in certain communities, such as younger patients, the Hispanic community, and the south[3, 4]. A
stroke is characterized by an acute focal loss of neurological function and is primarily caused by
loss of blood flow to a specific area of the brain. In 80% of strokes, loss of blood flow is due to a
blockage, which is known as ischemic stroke, while in 20% of strokes, blood loss is due to a leaking
or burst vessel, which is known as a hemorrhagic stroke [5]. There are many identifiable risk fac-
tors for stroke, including various metabolic, cardiovascular, and coagulative diseases, medications,
lifestyle, and demographics. In addition, “triggers” such as pollution, infection, and inflammatory
disorders can precipitate the acute event [5]. Accurate determination of the etiology of disease
is essential for risk stratification and optimal treatment, but this can be difficult as up to 35% of
strokes are of undetermined cause [6, 7]. Most of the unidentified risk, up to 40%, is thought to be
genetic [8]. Initial stroke GWAS found few variants of genome-wide significance with thousands
of participants[9, 8, 10]. The largest stroke genome-wide association study (GWAS) consisted
of a cohort of 520,000 participants, including 67,162 cases [11]. Even with this large number of
cases, the study only found thirty-two genome-wide significant variants for stroke, many fewer
than the hundreds to thousands of variants found for related stroke risk factors [12]. Since stroke
requires both genetic risk factors and environmental stimuli to manifest[5], patients with genetic
predisposition for the disease but without a stroke event would be considered controls. This type
of stringent classification may lead to loss of power [13]. A recent study improved predictability of
acute ischemic stroke by using a polygenic risk score that incorporated known risk factor variants
in addition to known acute ischemic stroke variants [12]. This highlights the potential for incor-
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porating medical data into case assignment to improve genetic signal and reduce information loss
from treating potential genetically susceptible subjects with known risk factors as controls.
Genome-wide association studies were first introduced as an unbiased answer to family linkage
and specific gene studies [14]. Initially, family linkage studies identified heritable diseases that
aggregated within families, but they discovered variants at a scale too small and biased towards
specific genes found within the studied families [13, 15]. From the earliest GWAS, the goal of
finding variants that contribute to disease required identification of as many people with the disease
as possible [14, 16, 17]. These variants, however, only accounted for a portion of heritability[14,
15, 17]. Later studies argue that much of this was due to overly conservative significance thresholds
or causal variants not inherited with the marker single nucleotide polymorphism (SNP)[13, 18,
19]. These causal variants may have been expressed at low frequency, which supports the need to
maximize the sample size and to develop high throughput methods for identifying these cohorts[13,
17, 16].
Therefore, an essential task for genetic studies is to define who has the disease[13]. In a ge-
netic context, it requires choosing the best representation of the genotype, or genetic makeup of the
subject, through the phenotype, or physical manifestation of the genotype[20, 21]. The phenotype
can be described through appearance, characterization, behavior, and acute events stemming from
gene and environment interactions[22]. The field of phenomics and the human phenome project
developed from the recognition that missing heritability could be partially attributed to heterogene-
ity in the phenotype[16, 23]. With cohorts for genetic studies ballooning in size, a high-throughput
and accurate way to phenotype cohorts is essential[23]. High-throughput identification of cases
and controls can be difficult, however, due to time-consuming chart review and incompleteness of
medical records. Current GWAS require a large number of well-adjudicated cases for statistical
power[14, 17]. Convention argues that a cleaner phenotype at appropriate granularity for the study
disease results in a stronger genetic signal[17, 13]. This overlooks patients with a genetic predis-
position for the disease but may not have yet presented with the phenotype. In addition, the stroke
phenotype from individual to individual is heterogeneous, and its description is dependent on the
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data available. For example, stroke manifested in two different patients as hemiplegia and CT
imaging positive for a cerebral artery blockage may be caused by entirely different etiologies of
the disease, such as atrial fibrillation and stasis in the heart versus atherosclerosis. In most research
settings, it can be defined simply as a single International Classification of Diseases (ICD) code
for stroke[24]. A more holistic description of the phenotype can be defined within the electronic
health record, which has a rich assortment of information to describe a patient’s medical timeline.
The electronic health record has a long and successful history of use in genomic research even
though its primary purpose is for clinical coordination and billing[25, 26]. The UK Biobank is a
prospective study of 500,000 adults, aged 40-69, containing comprehensive questionnaires, phys-
ical measurements, imaging, EHR data, genotyping, and exome data[27, 28]. This resource is
openly used worldwide to study the genetics of thousands of diseases, social determinants, and
biological markers[29]. Some limitations of the UK Biobank include lack of visit dates and lack
of diversity within the biobank, where 95% of participants are of European ancestry. This prevents
the incorporation of the medical timeline into patient phenotyping, which is possible in biobanks
directly linking EHR data. In addition, the lack of diversity can lead to missed common and rare
variants found in other ancestral backgrounds[15, 30, 31]. More recent biobanks, such as the All of
Us Research Program in the United States, are aiming to fill the gap in diversity[30]. The electronic
Medical Records and Genomics Network (eMERGE) consortium is a large collaboration across
nine major academic medical centers combining biobanks of patients with their electronic health
record data. They also develop and maintain pheKB, a library of fifty-five rule-based phenotyping
algorithms which have been validated across other sites with a positive predictive value of at least
90%. Their large cross-institution data set and stringent phenotyping have resulted in hundreds of
publications including many successful genome-wide association studies[32, 33, 34, 35]. Some of
the difficulty in replication of phenotypes across sites, however, are due to implementation of the
algorithms. Many require natural language processing and inclusion/exclusion criteria that may
be recorded differently across sites. PheKB algorithms translated into the Observational Health
Data Sciences and Informatics (OHDSI) Observational Medical Outcomes Partnership Common
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Data Model (OMOP CDM) transferred better across institutions over the original phenotype algo-
rithms[36, 37]. The OHDSI OMOP CDM is a world-wide community-driven standardized model
for organizing electronic health record data and mapping the data to vocabularies and terminolo-
gies for research[38]. Major healthcare centers around the world have formatted their EHR data to
the OMOP CDM, leading to observational research studies with hundreds of millions of patients
and over a billion data points[39, 40, 41]. The OMOP CDM provides the base necessary to develop
high-throughput phenotyping within the EHR.
There are biases unique to phenotyping with EHR data since its primary uses are for patient
care and billing. Often, the data are incomplete and missing not at random. Diagnoses codes
are issued and tests ordered when doctors need them, and data completeness depends on patient
interactions with healthcare, such as having insurance or choosing not to seek care [42, 26, 25,
43, 44]. This can lead to a bias in algorithms assessing patient disease risk towards patients who
frequently seek health care[45]. In addition, since only a portion of people with a given disease
seek help, generalizing outcomes from the patients can be problematic[26]. Finally, diagnosis
codes can often be chosen for reimbursement purposes rather than actual diagnosis, and diagnosis
code use can change over time, leading to inaccuracies in phenotyping[43, 25].
Despite these caveats, successful phenotyping has combined specific data domains and vocab-
ularies within the OMOP CDM[36, 37]. The data contains seven domains, including conditions,
procedures, measurements (lab values), drugs (medications), devices, observations (such as social
history), and visits (type of visit, such as inpatient)[46]. Not all domains are populated with every
CDM implementation, but the most common are conditions, procedures, measurements, drugs,
and visits. Within conditions, which represent patient diagnoses, the International Classification of
Disease codes, version 9 and 10 (ICD9 and ICD10) and Systematized Nomenclature of Medicine
(SNOMED) codes are most commonly used[46]. ICD9 and ICD10 codes tend to be more sensitive
over specific, while Current Procedural Terminology (CPT) codes, used for procedures, are more
specific but have low recall across sites[47]. In addition, for diseases with easily detectable symp-
toms, such as stroke, the less likely a false positive diagnosis label will occur[42]. For diseases
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that are diagnosed or confirmed by lab values, the measurement domain is shown to have high
precision, and medications are also a good confirmatory data type[47].
Not only can phenotypes be richly described by the information in the EHR, but high through-
put screening for diseases worth pursuing through GWAS can be performed. Highly heritable
diseases, for example, have a strong genetic susceptibility[48]. Several papers have developed
high-throughput methods for estimating disease heritability without genetic data. Studies have
inferred genetic overlap between disease co-occurrences in millions of patients[49], estimated
high-throughput heritability through building familial relationships through insurance claims[50],
and developed an algorithm that creates EHR-derived pedigrees by inferring familial relationships
through emergency contact information[51]. These methods estimate the heritability of hundreds
of diseases without genetic information and rely on single insurance billing diagnosis codes to phe-
notype the patients. Another study further teased apart genetic versus environmental contribution
to phenotypic variance using insurance claims and phenotyped cases using phecodes, which are a
manually agglomerated group of ICD9 and ICD10 codes to represent a phenotype[52, 53].
The heterogeneous nature of diseases such as stroke is another source of loss of power in
GWAS, suggesting a need to conduct individual genetic studies on disease subtypes[17, 54]. Tra-
ditionally, subtyping a patient requires a time consuming and laborious process of integrating mul-
tiple facets of data, including medical notes, labs, and imaging reports with medical experience
by physicians[55]. There is an opportunity for an unsupervised data-driven subtyping method
to complement the physician-defined approach to phenotyping. The most common unsupervised
subtyping categories are clustering, dimensionality reduction, topological data analysis, and deep
learning[54]. Factorization and dimensionality reduction methods are common data-driven ap-
proaches to identify subtypes[56, 57, 58, 59, 60]. They can model interactions between items while
also de-emphasizing missing data. Non-negative matrix factorization is a dimensionality reduction
method to learn representation of parts. The method imposes non-negative constraints on its fac-
torization, so all components are additive[61]. Mixed membership models such as Latent Dirichlet
Allocation and semi-supervised mixed membership models have identified different disease phe-
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notypes from heterogeneous data in the electronic health record[62, 63]. In addition, Bayesian
factorization methods such as hierarchical Poisson factorization have been used in the past to sub-
type customers for recommender systems because of their ability to capture interactions of a user
with a set of items while also taking into account sparsity of data, large variation in interaction
frequency, and deemphasizing the weight of zeros[64]. Levitin et. al. applied hierarchical Poisson
factorization to determine novel transcriptional patterns of genes in single cell RNA-seq data to
separate different cell types within tissues and predict patient survival from glioblastoma[65].
In addition, deep learning has been applied to the subtyping field. Deep learning uses neural
networks to process large amounts of features and find novel patterns within the data[66]. Denois-
ing autoencoders (DAs) are a type of neural network that reconstructs an input through a hidden
layer, compressing thousands of features, or inputs, to a more compact representation[67, 68]. DAs
have been used to predict disease susceptibility to many different diseases[69], to predict survival
in ALS patients[68], and to successfully separate subtypes of simulated patients[67]. Reducing
phenotypic heterogeneity can improve genetic signal within subtypes[58]. Li et. al[70] found three
novel subtypes of Type 2 diabetes applying topological data analysis to clinical data enriched for
subtype-specific genetic variants. This reinforces the usefulness of subtyping to increase genetic
homogeneity of cohorts.
In this thesis, we explore three aims to improve phenotyping for genetic studies, particularly
when applied to stroke. In Aim 1, we develop a phenotyping algorithm to differentiate between
acute ischemic stroke patients and other similar diseases (Chapter 2). In Aim 2, we compare two
unsupervised learning algorithms to subtype acute ischemic stroke with more granularity and with
less manual labor than current methods (Chapter 3). Finally, in Aim 3, we develop QTPhenProxy, a
quantitative trait proxy that uses the phenotyping algorithms’ probability output from Aim 1 to im-
prove the power of estimating heritability and genome-wide significant variants within Columbia’s
electronic health record and eMERGE data set (Chapter 4) and the UK Biobank (Chapter 5).
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Chapter 2: Comparative analysis, applications, and interpretation of
EHR-based stroke phenotyping methods
2.1 Introduction
Stroke is a complex disease that is a leading cause of death and severe disability for millions
of survivors worldwide[1]. Accurate identification of stroke etiology, which is most commonly
ischemic but encompasses several other causative mechanisms, is essential for risk stratification,
optimal treatment, and support of clinical research. While electronic health records (EHR) are
an emerging resource that can be used to study stroke patients, identification of stroke patient
cohorts using the EHR requires the integration of multiple facets of data, including medical notes,
labs, imaging reports, and medical expertise of neurologists[55]. This process is often manually
performed and time-consuming, and can reveal misclassification errors[71, 55].
One simple approach to identify acute ischemic stroke (AIS) is the diagnosis-code based algo-
rithm created by Tirschwell and Longstreth[24]. Identifying every AIS patient using these criteria,
however, can be difficult due to the inaccuracy and incompleteness of diagnosis recording through
insurance billing[24, 72, 44]. Past studies have shown that the positive predictive value (PPV),
sensitivity, and specificity of identifying stroke using ICD9 codes varies widely depending on
cohort and data available [24, 73, 74, 75, 76, 77, 78]. Additionally, this approach prevents the
identification of AIS patients until after hospital discharge, thereby limiting the clinical usabil-
ity of identification algorithms in time-sensitive situations, such as in-hospital care management,
research protocol enrollment, or acute treatment. Reproducibility and computability of phenotyp-
ing algorithms stem from the use of structured data, standardized terminologies, and rule-based
logic[79]. Phenotyping features from the EHR have been traditionally culled and curated by ex-
perts to manually construct algorithms[80], but machine learning (ML) techniques present the
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potential advantage of automating this process of feature selection and refinement[81, 82, 83, 84].
Recent machine learning approaches have also combined publicly available knowledge sources
with EHR data to facilitate feature curation[85, 86]. Additionally, while case and control pheno-
typing using EHR data has also relied on a small number of expert curated cohorts, recent studies
have demonstrated that ML approaches can identify such cohorts using automated feature selec-
tion and imperfect case definitions in a high-throughput manner[87, 88, 89, 90]. Within these ML
methods, the selection of cases and controls using diagnosis codes can significantly affect model
performance[91]. Feature size can also influence the utility of the model. Structured medical data,
in particular, have hierarchical organization that can be utilized for the grouping of similar features
and have improved classification performance[92, 93]. Finally, interpretation of the ML pheno-
typing model relies on a calibration assessment[94]. Calibration provides a way to understand the
clinical utility of the phenotyping model.
Two stroke phenotyping algorithms have used machine learning to enhance the classification
performance of a diagnosis-code based AIS phenotyping algorithm[77, 78, 95, 96]. Ni et al. man-
ually curated hundreds of features and confirmed that machine learning classifiers outperformed
stroke ICD9 codes and research nurses’ review on all metrics except recall[77]. Imran et al. de-
veloped a knowledge-driven phenotyping algorithm to define a gold standard of stroke cases from
physician review and found that logistic regression trained with only ICD9 codes for acute is-
chemic stroke as features outperformed ICD9 AIS codes defined by Tirschwell and Longstreth
in sensitivity and specificity[78]. While ML models present an opportunity to automate identifi-
cation of AIS patients (i.e. phenotyping) with commonly accessible EHR data and develop new
approaches to etiologic identification and subtyping, the optimal combination of cases and controls
to train such models remains unclear.
Given the limitations of manual and diagnosis code cohort identification, we sought to de-
velop phenotypic classifiers for AIS using machine learning approaches, with the objective of
specifically identifying AIS patients that were missing diagnosis codes. Additionally, consider-
ing the challenge of identifying true controls in the EHR for the purpose of model training, we
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also attempted to determine the optimal grouping of cases and controls by selecting and compar-
ing model discriminatory performance with multiple case-control group combinations. We also
sought to contrast model trained on cases defined by diagnostic codes with manually-curated co-
horts. We also applied key methods to optimize the robustness of these models to missing data, the
calibration to ensure a clinically meaningful model output, and the number of features to improve
generalizability. We then applied the models to all 6.4 million patients in our EHR to estimate the
prevalence of potential stroke patients that do not have ICD codes for AIS. We tested one of our
best-performing models in an independent test set, the UK Biobank, to evaluate its ability to detect
self-reported AIS patients without the requisite ICD codes. Our phenotyping method utilizes ma-
chine learning classifiers with minimal data processing to increase the number of stroke patients
recovered within the EHR and reduces the time and effort needed to find them for research studies.
2.2 Objective
The aim of this chapter is to develop and evaluate a machine learning algorithm to phenotype
ischemic stroke patients in the EHR for research purposes. We hypothesize that the addition of
EHR data will identify features in addition to ICD9 and ICD10 AIS codes that can phenotype
these patients in a data-agnostic manner.
2.3 Methods
2.3.1 Study Design
In this study, we developed several machine learning phenotyping models for AIS using com-
binations of different case and control groups derived from our institution’s EHR data. Use of
Columbia patient data was approved by Columbia’s institutional review board and UK Biobank
data approved with UK Biobank Research Ethics Committee (REC) approval number 16/NW/0274.
Figure 1 shows the overall workflow of training and testing the models, the models’ evaluation,
and its testing in an independent test set.
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2.3.2 Data Sources
We used data from patients in the Columbia University Irving Medical Center Clinical Data
Warehouse (CUIMC CDW), which contains longitudinal health records of 6.4 million patients
from CUIMC’s EHR, spanning 1985-2018. The data include structured medical data such as con-
ditions, procedures, medication orders, lab measurement values, visit type, demographics, and
observations. The data are organized into tables and standardized vocabularies and terminologies
in the format of the Observational Health Data Sciences and Informatics (OHDSI) Observational
Medical Outcomes Partnership Common Data Model (OMOP CDM)[38]. This includes patients
from the CUIMC stroke service (Figure 2.1, Table 2.1) that were part of a larger group of patients
with acute cerebrovascular diseases, were prospectively identified upon admission to New York
Presbyterian Hospital, and recorded as part of daily research activities by a CUIMC stroke physi-
cian between 2011 and 2018. Two researchers (Phyllis Thangaraj (PT) and Benjamin Kummer
(BK)) each manually reviewed 50 patients’ charts for a total of 100 patients from this cohort to
determine baseline false positive rates.
2.3.3 Patient Population
We defined three case groups. We first included all patients from the CUIMC stroke ser-
vice with recorded with AIS (cohort S). We then defined all patients in the CDW that met the
Tirschwell-Longstreth (T-L) diagnosis code criteria for AIS (cohort T), which comprise ICD9
codes 434.x1, 433.x1, 436 (where x is any number), and the code is in the primary diagnostic
position[24]. Our dataset did not specify the diagnostic position of codes. We also included
ICD10 code equivalents, I63.xxx or I67.89, with the ICD10 codes determined from ICD9 from
Centers for Medicaid and Medicare Services (CMS) General Equivalence Mappings[97]. Because
patients with cerebrovascular event diagnosis codes such as transient ischemic attack or migraine
aura with cerebral infarction may have suffered AIS but may not have an attached AIS diagnosis
code, we also created a group of cases with cerebrovascular disease-related ICD codes defined by
the ICD-9-Clinical Modification (CM) Clinical Classifications Software tool (CCS). This includes
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ICD9 codes 430-438 and 346.xx as well as their ICD10 equivalents, I60.xxx-I66.xxx, R29.xxx,
and G43.xxx (cohort C)[98]. We then defined four control groups (Figure 2.1, Table 2.1). First, we
defined a control group of patients without AIS-related diagnosis codes (I). Since cerebrovascular
disease is a major risk factor for stroke[5] and to test a more stringent control definition than that
of group (I), we also defined an additional group without any of the CCS cerebrovascular disease
codes defined in cohort (C). Then, we defined a control set using CCS cerebrovascular disease
diagnosis codes other than AIS (CI). Because multiple clinical entities can present as AIS, we also
defined a group of controls according to diagnosis codes for AIS mimetic diseases (N), includ-
ing hemiplegic migraine (ICD9-CM 346.3), brain tumor (191.xx, 225.0), multiple sclerosis (340),
cerebral hemorrhage (431), and hypoglycemia with coma (251.0). Finally, we identified a control
group culled from a random sample of patients (R).
2.3.4 Model Features
From the CDW, we gathered race, ethnicity, age, sex, diagnostic and procedure insurance
billing codes as well as medication prescriptions for all patients. We dichotomized each feature
based on its presence or absence in the data. Because Systematized Nomenclature of Medicine
(SNOMED) concept IDs perform similarly to ICD9 and ICD10 codes for phenotyping[99, 100],
we mapped diagnoses and procedure features from ICD9, ICD10, and Current Procedural Ter-
minology 4 (CPT4) codes to SNOMED concept IDs and used RxNorm IDs for medication pre-
scriptions. We identified patients with Hispanic ethnicity using an algorithm combining race and
ethnicity codes[51]. The most recent diagnosis in the medical record served as the age end point,
and we dichotomized age as greater than or equal or less than 50 years. Importantly, we excluded
from our feature set any diagnosis codes that were used in any case or control definitions. Because
approximately 5 million patients exist in the CUIMC CDW without a cerebrovascular disease di-
agnosis code, there is a large imbalance between cases and controls, which can lead to a machine
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Variable Identification N Samples
Total Patients CUIMC CDW Person ID 6,377,222
Diagnosis Codes ICD9,ICD10,SNOMED 140,300,457
Procedure Codes ICD9,ICD10,CPT,SNOMED 64,383,775
Prescription Orders RxNorm 40,759,814
Training Categories
Stroke Service Cases (S) Seen by NYP Stroke Service 4,484
Tirschwell Criteria AIS Cases (T) ICD9:434.x1,433.x1,ICD10:I63.xxx 79,306
CCS Cerebrovascular Cases (C) ICD9:346.6x,430,431,432.x,433.xx 181,698
AIS Mimetic Diseases Controls (N) ICD9:191.x,225.x,340,250.0,431 8,438
No Stroke Controls (I) No (T) Codes 5,243,646
No Cerebrovascular Disease Controls (C) No (C) Codes 5,149,975
Cerebrovascular disease, w/o AIS Controls
(CI)
(T) codes, No (C) codes 102,435




Total Subjects With diagnoses codes, proce-
dure codes, medication pre-
scriptions, or demographics
384,208
Tirschwell Criteria AIS Cases (T) ICD10:I63.xxx,I64.x,(41202,
41204)
4,922
No Cerebrovascular Disease Controls (C) No (C) Codes (41202, 41204) 312,500
Subjects with AIS but no diagnosis codes Date of AIS (42008) - (T) cases 163
Table 2.1: Select Structured Data and Sample Case/Controls for models available in CUIMC
Common Data Warehouse.
learning classifier that undersamples cases[91]. By randomly sampling controls in a 1:1 case to
control ratio, we created a balanced dataset. In addition, we set the maximum sample size to 16,000
patients in order to control the size of the feature set.
2.3.5 Model development
Using all 15 case-control combinations, we trained 75 models using logistic regression classi-
fiers with L1 and elastic net regularization as well as random forest, AdaBoost, gradient boosting,
and neural network classifiers on the gathered features. We chose these classifiers to compare a
variety of feature-to-outcome relationships: linear (logistic regression), ensemble (random forest,
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Figure 2.1: Schematic of Model Training, Testing, Evaluation, and Application to UK
Biobank. Cases: 1) Physician curated, stroke service patients (S), 2) Patients with stroke in-
surance billing codes (I), 3) Patients with cerebrovascular disease billing codes (C) Controls: 1)
Stroke mimetic neurological diseases (N), 2) Sample of patients in EHR without stroke code (I),
3) Sample of patients in EHR without cerebrovascular disease codes (C), 4) Sample of patients
in EHR with cerebrovascular disease codes but without stroke codes or not gold standard (CI) 5)
Random sample in EHR (R). Case: Control ratio was 1:1 and models included Random Forest
(RF), Logistic Regression with L1 penalty (LR), Neural Network (NN), Gradient Boosting (GB),
Logistic Regression with Elastic Net Penalty (EN) and Adaboost (AB). Area Under the Receiver
Operating Curve (AUROC), Area under the Precision Recall Curve (AUPRC), Sensitivity (Sens),
Specificity (Spec), Positive Predictive Value (PPV), Negative Predictive Value (NPV).
AdaBoost, gradient boosting), and non-linear (neural network). We tuned the models’ hyperpa-
rameters using 10-fold cross validation. We ran a grid search for the hyperparameters of maximum
tree depth, number of estimators, L1-L2 ratio, penalty parameters, subsampling rate, learning rate,
momentum, and dropout. Outside of the default parameters, we used a max tree depth of 100,
1000 estimators, and square root maximum feature number for the random forest models. For L1
Logistic regression, we used an inverse of regularization strength of 0.1, and for elastic net regular-
ization, we used a penalty parameter of 0.01 and L1-L2 ratio parameter of .01, and "log" loss. For
the boosting algorithms, we used a learning rate of 0.1, 1000 estimators, and for gradient boosting
we also subsampled at a rate of 0.5, max depth as 10, and square root maximum feature number.
The neural network model was comprised of two layers, the first with 64 neurons, relu activator,
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and l1 kernel regularizer. The second layer contained two neurons and a softmax activator. Learn-
ing was compiled by stochastic gradient descent with a learning rate of 0.01 and momentum of 0.9,
nesterov=True. We included a dropout of data in the first layer at a rate of 0.3. Loss was calculated
by categorical cross-entropy. We then determined a probability threshold for each model from the
training set. Within the validation set of each training fold, controls were bootstrapped to form
a 100:1 control to case ratio to represent the prevalence of AIS in the population[1]. Precision
and recall were then calculated from the bootstrapped set. To determine the optimal threshold to
maximize precision while maintaining a high recall, we calculated maximum F scores at different
βs using the following equation:
Fβ = (1 + β2) ∗ precision ∗ recall(β2 ∗ precision) + recall
where β = 1.0, 0.5, 0.25, and 0.125. Using the probability threshold determined from cross-fold
validation, we then calculated the maximum F1 score, sensitivity, specificity, positive predictive
value, negative predictive value, and precision on a holdout set of 1000 patients from the stroke
service and 100,000 non-overlapping randomly selected patients. We chose this test ratio to imitate
the prevalence of AIS in the general population. The models were evaluated on the test set with area
under the receiver operating curve (AUROC) and average precision score (AP), a proxy for area
under the precision-recall curve. All models were programmed using the Python sklearn scientific
computing package (Python Software Foundation, www.python.org)[101]. We then aggregated
common features found in the top ten in importance or beta coefficient weight for each model,
and we evaluated the contribution of each feature to each model by comparing its prevalence in
the cases with its prevalence in the controls and as a function of its importance (or weight) in the
model.
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2.3.6 Robustness of model
To test the robustness of the models, we trained on 100%, 90%, 70%, 50%, 30%, 10%, 5%, 1%,
0.5%, and 0.1% of the original training set. We then evaluated the performance of each training
size on the test set through AUROC and AP. We resampled the set 10 times at each training size
and averaged the results.
2.3.7 Calibration
The classifiers assign a probability of being an AIS case to each patient. In order to interpret
the meaning of these model probabilities and their applicability to other patients, we developed an
empirical calibration method for the models. For each training fold during 10-fold cross validation,
we first sorted the probabilities by value. We then averaged a bin of 100 patients intervals based on
their assigned probability (predicted probability). Within each bin, we calculated the proportion of
cases (actual probability). We repeated this sliding bin, averaging for every 10 patients, creating an
empirical function between the training set predicted probabilities and actual probabilities averaged
across training folds. We then repeated the same averaging of predicted and actual probabilities for
the sorted test set. We calibrated the test set predicted probabilities using the empirical function
generated from the training folds. To evaluate calibration success, particularly for identifying
cases, we calculated the root mean squared error (RMSE) of all calibrated test probabilities larger
than 0.1. We made this cut off because many of the poorly calibrated models have many points
near zero, giving a false low RMSE score. Models without any calibrated probabilities larger than
0.1 were given an RMSE of ’N/A’.
2.3.8 Feature collapsing
Reduction of feature size is also essential for reproducibility of the models in other hospital
settings. Our approach collapses features together by utilizing the hierarchical structure of ICD9,
ICD10, and CPT4 diagnosis codes and procedure codes, and ATC ingredient definitions for medi-
cations. We mapped ICD9 and ICD10 diagnosis and procedure codes and drug prescription order
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ingredients to SNOMED CT concept IDs. About 40% of the features could not be mapped auto-
matically to SNOMED concepts, so we kept codes and ingredients that did not have concept IDs as
separate features. We then mapped ICD9 codes to ICD10 codes using General Equivalence Map-
pings [97]. We mapped all ICD9 and ICD10 diagnosis and procedure codes and CPT4 procedure
codes to the Clinical Classifications System defined by the Health Cost and Utilization Project [98,
102, 103, 104, 105]. The CCS has flat level codes (most granular), and multilevel codes level 1-3
(least to most granular). We mapped all codes to the flat, multilevel level 1 and multilevel level 2
codes. We then mapped drug prescription ingredients to ATC codes by matching corresponding
RxNorm codes to ATC codes. Some drugs required manual mapping to ATC codes. All in all,
we successfully mapped 70% of 45 million prescription orders to ATC codes. We then reduced
prescription order features to the five different levels of ATC, which include, in increasing order
of specificity, anatomical systems (14), therapeutic subgroups (78), pharmacological subgroups
(159), chemical subgroups (364), and chemical substances (895). We then reran the training sets
with collapsed features in three combinations: flat CCS level with chemical substrates (the most
granular), multilevel CCS level 2 with pharmacological subgroups, and multilevel CCS level 1
with anatomical systems (the least granular). We chose these pairings to maintain similar ratios of
drugs and ICD9 and ICD10 codes. We evaluated the robustness of hierarchical feature collapsing
using the method described above. We then compared performance across levels of granularity
using AUROC and average precision score, which is a proxy for area under the precision-recall
curve.
2.3.9 Generalized linear model to determine feature category contribution to models
To further explore the contribution of conditions, procedures, drugs, and demographics, to the
models’ classification performance, we ran a multivariate generalized linear model (GLM) on the
stroke probabilities generated from each feature category. We retrained the models solely using
features from each category. We also added a fifth category, which comprised the ICD9 codes
that make up the T-L criteria and ICD10 equivalent codes (see Table 2.1). We added this category
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to compare the performance of the T-L criteria to the other features in AIS patient classification
because our models do not include the T-L criteria in training. We then generated AIS probabil-
ities for the holdout test set using each of the retrained models. Finally, we combined the model
probabilities from each of the five models and ran the generalized linear model with binomial dis-
tribution to determine which categories significantly (p < .05) contributed to case determination
and their corresponding beta coefficients.
2.3.10 Internal validation using all EHR patients
To identify the number of patients classified as having AIS in our institutional EHR, we applied
each of the 75 models to the entire patient population in the CUIMC CDW with at least one
diagnosis code. We chose a probability threshold based on the maximum F1 score determined for
each model from the training set. We also determined the percentage of patients that had AIS ICD9
codes as defined by T-L criteria and associated ICD10 codes.
2.3.11 External validation of acute ischemic stroke patient classification in the UK Biobank
The UK Biobank is a prospective health study of over 500,000 participants, ages 40-69, with
comprehensive EHR and genetic data[106]. Given that this dataset contains 4,922 patients with an
AIS related ICD10 code, similar to our T case cohort, and 163 patients without AIS related ICD10
codes, the UK Biobank can evaluate our machine learning models’ ability to recover potential AIS
patients that lack AIS-related ICD10 codes. One difference between the UK Biobank definition
of the AIS related ICD10 codes and our definition is their addition of code I64, which translates
as “Stroke, not specified as haemorrhage or infarction”. We chose the most accurate and robust
case-control combination from our models (cases defined by the T-L AIS codes (T) and controls
without codes for cerebrovascular disease (C) in a 1:1 case-control ratio as our training set) to
train the phenotyping model using conditions specified by ICD10 codes, procedures specified by
OCPS4 codes, medications specified by RxNorm codes, and demographics as features, excluding
features that were used to create the training and testing cohorts. We trained on half of the patients
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with AIS related ICD10 codes, and then tested our models on the rest of the UK Biobank data,
which included AIS cases without AIS ICD10 codes and the other half of the patients with AIS
related ICD10 codes. We added these patients to improve the power of detecting cases, and we
removed the AIS related ICD10 codes from our feature set to prevent recovery of patients due to
these codes. We resampled the control set 50 times and evaluated the performance of the algorithm




Table 1 presents the data and the total number of patients available for each set of cases and
controls used in the training and internal and external validation parts of this study. Out of the
CUIMC EHR, which has a total of 6.4 million patients, we extracted 4,844 stroke service patients,
which we found to have a 4-16% false positive rate for stroke. Table 2.2 presents demographic
characteristics.
Table 2.2: Demographics of Case-control cohorts
2.4.2 Algorithm Performance
We trained 75 models using all combinations of cases, controls, and model types after exclud-
ing 15 neural network models due to poor performance. Logistic regression classifiers with L1
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Figure 2.2: Performance of select models on holdout test set ((a): AUROC, (b): F1).(LR) logistic
regression with l1 penalty, (RF) random forest, (AB) AdaBoost, (GB) gradient boosting, (EN)
logistic regression with elastic net penalty. Different combinations of cases and controls are shown
on the y-axis. Cases (first letter) may be one of cerebrovascular (C), T-L (T), or Stroke Service
(S). Controls (second and third letters) may be one of random (R), cerebrovascular disease but no
AIS code (CI), no cerebrovascular disease (C), no AIS code (I), or a stroke mimetic disease (N),
see Method 2.3.3 and Table 2.6 for definitions of sets. Threshold to compute the F1 score on the
testing set was chosen as the threshold that yielded the maximum F1 in cross-validation on the
training set, see Method 2.3.5
penalty gave the best AUROC performance (0.913-0.997) and the best average precision score
(0.662-0.969), followed by logistic regression classifiers with elastic net penalty (Figure 2.2a).
Across all classifier types, the TC model had the best average F1 score (0.832±0.0383), which
is a measure of the harmonic mean of precision and recall. Logistic regression models with L1
penalty (LR) and Elastic Net penalty (EN) had the best classifier average F1 score (0.705 ± 0.146
and 0.710 ± 0.134 respectively) (Figure 2.2b). Stroke service cases gave the highest average
precision (0.932 ± 0.0536), while cases identified through AIS codes and controls without cere-
brovascular disease or the AIS codes (TC, TI) gave high precision as well (0.896 ± 0.0488 and
0.918 ± 0.0316, respectively). The sensitivity of the models ranged widely, between 0.18 and
0.96, while specificity narrowly ranged between 0.993-1.0 (Table 2.3). Precision at top 50 and 100
patient probabilities was very high, 0.99-1.00, for all classifiers except EN. Precision at top 500
patient probabilities was high except for the TCI, TR, CN, CCI, and CR models (Table 2.4).
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Table 2.3: Sensitivity, specificity, positive predictive value, and negative predictive value of
models on holdout test set. See Table 2.6 for case-control, model, and evaluator abbreviations’
definitions. Blue values > 0.85, yellow values between 0.65 and 0.85, red values < 0.65.
Table 2.4: Precision at top 50, 100, and number of known cases for each classifier. Blue values
> 0.99, yellow values between 0.9 and 0.99, orange values between 0.7 and 0.9, red values < 0.7.
2.4.3 Feature importances
We aggregated common features found in the top ten in importance or beta coefficient weight
for each model, as seen in Figure 2.3A. We found the most commonly chosen features were pro-
cedures used in evaluation of AIS, including extra and intra-cranial arterial scans, CT scans and
MRIs of the brain, and MR angiography. We also found age over 50 to be a top common demo-
graphic feature, and Aspirin and atorvastatin (a cholesterol lowering medication) to be important
medication features. Top diagnosis features included unspecified essential hypertension, history of
transient ischemic attack or stroke without residual effect, pulmonary congestion and hypostasis,
convulsions, and iatrogenic cerebrovascular infarction or hemorrhage. We also evaluated the con-
tribution of each feature to each model by comparing its prevalence in the cases with its prevalence
in the controls and as a function of its importance (or weight) in the model. Figure 2.3B plots
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one of the 75 models, TC case-control combination with an adaboost classifier. We found that
all 75 models relied on incremental contributions from many different features (figs. 2.3 and 2.24
to 2.38).









CT head or brain; no contrast (2211327) 64% 54% 14% 
Age > 50 57% 85% 50% 
Duplex scan of extracranial arteries; bilateral (2313975) 55% 28% 8% 
Aspirin (1112807) 44% 61% 18% 
MRI, Brain and Brain stem; no contrast (2211351)  37% 36% 7% 
Transcranial Doppler study intracranial arteries (2313977) 33% 12% 1% 
Atorvostatin (1545958) 32% 48% 11% 
Unspecified essential hypertension (44821949) 31% 64% 26% 
MR angiography, neck, no contrast (2211348) 27% 55% 4% 
Level IV- Surgical pathology, gross, and microscopic… 
(2213283) 
27% 28% 24% 
Pulmonary congestion and hypostasis (44825477) 20% 30% 3% 
History of TIA or stroke w/o residual effect (45576200) 19% 6% 0.7% 
Convulsions (44823442) 16% 3% 2% 
Iatrogenic cerebrovascular infarction or hemorrhage (44834124) 13% 3% 0.3% 
!
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Figure 2.3: A) Common top 10 features in the models,(B) Prevalence of features in cases vs
controls in the TC AB model. (A) After each of the 75 models were trained, we counted the
number of times each feature was represented as one of the top ten by absolute coefficient weight,
for methods like logistic regression, or by feature importance, for methods like random forest.
Above are features from this analysis along with the proportion of models in which they were in
the top ten (% Models), the average frequency in the cases (Ave. Freq. Cases) and the average
frequency in the controls (Ave. Freq. Controls). (B) Axes were on a logarithmic scale. Increasing
size of blue dot correlates with higher feature importance or beta coefficient weight, depending on
the classifier type. Gray dots are features with zero importance.
2.4.4 Feature reduction and subsequent algorithm performance.
The number of features of the models ranged from 22,000-35,500 depending on case-control
combination and classifier type. We evaluated the performance of collapsing features by ICD9
and ICD10 and Anatomical Therapeutic Chemical Classification System (ATC) code hierarchy,
reducing the number of features per model to 72-1500 features, depending on the class size and
collapsing level (see Method 2.3.8). As seen in Figure 2.4, we found a 9-27% reduction in AUROC




Figure 2.4: Performance of models at increasing level of feature hierarchical collapse. Logistic
regression with L1 penalty (LR), Logistic Regression with elastic net penalty (EN), random forest
(RF), AdaBoost (AB), gradient boosting (GB), and a two-layer neural network (NN). (a) The area
under the receiver operating characteristic curve (AUROC) for each of the models versus the level
of abstract with ‘First’ being the lowest level of abstraction and ‘Third’ being the highest. (b) AP,
annotation described in (a).
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2.4.5 Calibration
We calibrated the models to the training set results to produce meaningful probability estimates
(See Method 2.3.5, Figure 2.5 and supplementary material). We found a wide range of success
in calibration of the models. Uncalibrated, the AdaBoost classifier produced a narrow range of
probabilities, between 0.4 and 0.6, while the other models ran a range of probabilities from 0 to
1. On average, test set calibration of the AdaBoost models had the lowest root mean squared
error (RMSE). The AdaBoost models with controls without cerebrovascular disease codes (C)
showed the lowest RMSE for each respective case set (RMSE=0.0917 (SC), 0.1212 (TC), and
0.1779 (CC)). Models with no calibrated predicted probabilities above 0.1 were given an RMSE
of N/A, and this applied to 23 of the models. These models mostly had a case set of patients
with any cerebrovascular disease code (C) or used a gradient boosting classifier. Notably, the
logistic regression model with L1 penalty with S cases and random (R) controls or controls with
cerebrovascular disease but no stroke (CI) had uncalibrated test set probabilities with low RMSE,
but high RMSE after calibration (see figure 2.12, figure 2.13).
2.4.6 Robustness
We evaluated the robustness of the models to increasingly smaller training sets (Figure 2.6,
2.7). When stratified by classifier type, all classifier types except AdaBoost maintained at least
80% of its AUROC performance with 1% of the training size (70-160 samples) and maintained at
least 70% of its AP performance with 5% of the training size (350-800 samples). When stratified
by case, models with stroke service cases (S) maintained at least 96% of its AUROC performance
with 1% of the training size (∼70 samples) and maintained at least 94% of its AP performance
with 5% of the training size (∼350 samples). Other cases (T, C) maintained at least 92% of its AU-
ROC performance and 77% of its AP performance with 5% of the training size (∼350 samples).
When stratified by control, models with stroke mimetic controls (N) maintained at least 99% of
its AUROC performance and 92% of its AP performance with 5% of the training size (350-635
samples). Random patient controls (R) maintained 88% of its AUROC performance and 75% of
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Figure 2.5: Classifier type with stroke service cases and without cerebrovascular disease (SC)
case-control combination varies in calibration success between stroke score, or model prob-
ability, and actual proportion of patients at each probability. Top panel plots the proportion
of stroke case patients within a bin of 100 patients with similar stroke scores for models trained
with stroke service cases and controls without cerebrovascular disease ICD9 or 10 codes. The
black circles plot the mean test stroke score across all training set folds, while the blue circles plot
the training fold stroke scores combined. Classifier type varies from left to right:Random Forest
(RF), AdaBoost (AB), Logistic Regression with L1 penalty (LR), Gradient Boosting (GB), Logis-
tic regression with elastic net penalty (EN). Bottom panel plots the proportion of stroke patients
within a bin of 100 test set patients with similar stroke scores versus the calibrated test scores at
specific scores rounded to the nearest thousandth (Black dots). The test scores are calibrated from
an empirical distribution determined from the training set 2.3.7. The blue dots plot the proportion
of stroke patients within a bin of 100 bootstrapped training set patients with similar stroke scores
versus the calibrated training set scores rounded to the nearest thousandth. The light grey dots
show perfect calibration.
its AP performance with 5% of the training size (350-800 samples). Controls without T-L AIS
codes (I) maintained at least 97% of its AUROC performance and 91% of its AP performance with
1% of the training size (70-160 samples) and 5% of the training size (350-800 samples), respec-
tively. Controls without cerebrovascular disease codes (C) maintained at least 91% of its AUROC
performance and 92% of its AP performance with 0.5% of the training size (35-80 samples) and
5% of the training size (350-800 samples), respectively. Finally, controls with cerebrovascular dis-
ease but without T-L AIS codes (CI) maintained at least 91% of its AUROC performance and 91%
of its AP performance with 5% of the training size (700-1600 samples) and 10% of the training
(1400-3200 samples), respectively. The SI case-control combination and EN classifier type model
was removed from Figure 2.6,2.7 and the above summary because of very high standard deviation
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(125-150% of value) that obscured the trends of the other models.






































































































































Figure 2.6: Robustness of models. Top: Normalized area under the receiver operating curve
(AUROC) across all case-control combinations. A: stratified by classifier type (LR, RF, AB,
GB, and EN), B: stratified by case type (first letter S,T,C), C: stratified by control type (second and
third letters: N, R, I,C,CI). Bottom: Normalized Average precision score (AP) values across all
case-control combinations, D: stratified by classifier type (LR, RF, AB, GB, and EN, E: stratified
by case type (first letter S,T,C), F: stratified by control type (second and third letters: N, R, I,C,CI).
Neural Network Models and EN GI model were removed from normalized graphs due to high
variance and obfuscation of other models’ trends.
2.4.7 Feature category contribution to models
We trained models on individual feature type categories (procedures, medications, conditions,
and T-L AIS conditions) and compared their contributions to model fit using nested linear models
(Method 2.3.9). We found that procedures contributed the most to model probabilities (Figure
2.8). 89% of the generalized linear model (GLM) models had a significant (p < 0.05) coefficient
weight for the procedure feature category, followed by medication orders, which made a significant
contribution in 59% of the models. The T-L AIS codes feature category, notably, was significant in
17% of the models. The beta coefficient of the T-L category was 2-20 times larger than the other
category coefficients.
25


































































































Figure 2.7: Robustness of models. Top panel, Left to Right: Area under the receiver operating
curve (AUROC) across all case-control combinations, A: stratified by classifier type (LR, RF, AB,
GB, and EN), B: AUROC across all models stratified by case type (first letter: S, T, C), C: AUROC
across all case-control combinations, stratified by control type (second and third letters: N, R,
I,C,CI). Bottom Panel, left to right: D: Average precision score (AP) values across all case-control
combinations, stratified by model, E: AP across all models stratified by case type, F AP across all
models stratified by control type. Neural Network Models and EN GI model were removed from
normalized graphs due to high variance and obfuscation of other models’ trends.
2.4.8 Internal validation in institutional EHR
We applied our models to the entire CUIMC EHR to estimate the prevalence of AIS patients
(Method 2.3.10). We trained 75 models using 15 case-control combinations and 5 classifier types
and then applied the models to the entire CUIMC EHR with at least one diagnosis code, totaling
5,324,725-5,315,923 patients depending on the case/control set. Based on the thresholds defined by
the maximum F1 score from the training set (see Method 2.3.5), we determined the prevalence of
AIS patients estimated in the EHR by each model. From these proposed cases, we also calculated
the proportion of patients with an ICD9 or ICD10 code for AIS defined by T-L. We found that
the results varied widely across models, but most predicted that a prevalence between 0.2-2% of
patients in the EHR were AIS patients. The models with controls with cerebrovascular disease




Figure 2.8: Feature category contribution to model fits. Top panel Left to right: A shows the
total number of models with a significant coefficient weight for each feature category, stratified by
classifier type. B shows the value of the significant coefficient weights, stratified by classifier type.
Bottom panel Left to right: C shows the total number of models with a significant coefficient weight
for each feature category, stratified by case-control type. D shows the value of the significant
coefficient weights, stratified by case-control type. TCI Random Forest model and CCI EN model
had significant coefficients in all categories, and all of these weights were greater than 10E14, so
they would be plotted beyond the scope of the y axis in B and D.
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of the proposed patients had AIS diagnosis codes. The models with the best performance and
robustness, 1) stroke service cases and controls without cerebrovascular disease codes and 2) cases
with AIS codes and controls without cerebrovascular disease codes with 1) Logistic Regression and
L1 Penalty classifier and 2) Adaboost classifier, had sensitivities between 0.822-0.959, specificities
0.994-0.999, and estimated AIS prevalence in the EHR ranging between 1.3-2.0% (see Table 2.3,
Table 2.5). Within these proposed AIS patients, 37.2-47.2% had an AIS diagnosis code (see Table
2.5).
Table 2.5: Prevalence of acute ischemic stroke patients identified by each classifier across the
EHR and proportion of those patients with T-L criteria. Prev=prevalence. See Table 2.6 for
case-control and model abbreviations’ definitions.
2.4.9 External validation of acute ischemic stroke patient classification in the UK Biobank
We evaluated the performance of the TC models to identify 2,624 patients without AIS ICD10
codes. As seen in Figure 2.9, the top 50, 100, 500, and 2,624 probabilities had a precision of over
29%, and up to 80%. Since within the test set only 0.5% of the patients had AIS, this translates to
a 60-150-fold increase in AIS detection over random choice.
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Figure 2.9: Precision-fold over random sampling of acute ischemic stroke cases without re-
lated ICD10 codes at top 50, 100, 500, and 2,624 patient probabilities assigned by machine
learning algorithms. With 95% confidence intervals in error bars. See 2.6 for model abbrevia-
tions’ definitions.
2.5 Discussion
2.5.1 Machine learned models are able to identify acute ischemic stroke patients without direct
evidence.
Using a feature-agnostic, data-driven approach with minimal data transformation, we devel-
oped models that identify acute ischemic stroke (AIS) patients from commonly-accessible EHR
data at the time of patient hospitalization without making use of AIS-related ICD9 and ICD10
codes as defined by Tirschwell and Longstreth. In demonstrating that AIS patients can be recov-
ered from other EHR-available structured clinical features without AIS codes, this approach is
in contrast to previous machine learning phenotyping algorithms, which have relied on manually
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curated features or used AIS-related diagnosis codes as the sole nonzero features in their models.
[77, 78, 24]. We show that AIS patients can be recovered from other EHR-available structured
clinical features excluding the T-L criteria.
2.5.2 Case and control choices are important for acute ischemic stroke phenotyping.
Case-control selection for phenotyping algorithms can be challenging to identify and define
given the richness of available EHR data. From the sparsity of diagnosis codes in the EHR, it fol-
lows that patients lacking an AIS-related diagnosis code may not always be considered a control in
stroke cohorts. Similarly, it is difficult to determine whether patients with cerebrovascular diseases,
which can serve as risk factors for AIS, or share genetic and pathophysiologic underpinnings with
AIS, should be considered controls. Additionally, due to the prevalence of AIS mimics, cohort
definitions based on diagnosis code criteria may be unreliable. In light of the problems in defining
patient cohorts from EHR data, we found marked differences in classifying performance across
15 different case-control training sets. While training with cases from the CUIMC stroke service
identified stroke patients most accurately and with the highest precision and recall, we also found
that training with cases identified from AIS codes with controls from either 1) no cerebrovascular
disease or 2) no AIS codes afforded high precision. These findings suggest that a manually curated
cohort may not be necessary to train the phenotyping models, and the AIS codes may be enough to
define a training set. Using these models, we also increased our AIS patient cohort by 60% across
the EHR, suggesting that the AIS codes themselves are not sufficient to identify all AIS patients.
2.5.3 Procedures serve as a proxy for acute ischemic stroke diagnosis codes in model features.
We found that stroke evaluation procedures, such as a CT scan or MRI, were important features
in many of the models. Since none of these models use AIS diagnosis codes as features, this
suggests that procedures may serve as proxies for AIS cohort identification. In some cases, the
AIS code will only be added during outpatient follow up. For example, in the stroke service set,
13.5% of cases did not have AIS codes in the inpatient setting but did in the outpatient setting,
30
and 90% of these patients had had a CT scan of the head. We found that procedures provided
a significant contribution (p < .05) to patient classification in 89% of the models, while the T-L
diagnosis codes provided a significant contribution in 17% of the models (though the T-L beta
coefficient was 2-20 times higher than the other categories). This suggests that procedures are
important proxy features for the T-L AIS diagnosis codes (Figure 2.3).
2.5.4 Other diagnosis codes may be useful for phenotyping acute ischemic stroke.
In addition, iatrogenic cerebrovascular infarction or hemorrhage (SNOMED ID 44834124,
ICD9 997.02) was found to be a top feature and is a code not within the cerebrovascular infarction
ICD9 code class. Although this code does not distinguish between an ischemic and hemorrhagic
stroke, it was found in 4% of cases and could be a useful addition for AIS cohort identification pur-
poses. Other conditions that were highlighted by the models include hemiplegia and convulsions.
This is consistent with features that may be coded during initial inpatient evaluation for a stroke.
In some cases, the actual AIS will only be coded during outpatient followup.
2.5.5 Models showed robustness to reduction of training set size, but not with code-hierarchy-
based feature reduction.
We found that as measured by AUROC and AP, discriminatory performance of the random
forest, logistic regression with L1 and elastic net penalties, and gradient boosting models was
robust, even when up to 95% of the training set was removed. These findings showed that a
training set size as small as 70-350 samples can maintain high performance, depending on the
model. However, reducing feature set size by collapsing with CCS and ATC hierarchy resulted
in large drops in performance, most likely due to the 95-99% drop in feature set size and high
level description of the features. This suggests that the feature reduction by hierarchical collapse
trains with excessively high-level features, leading to unsuccessful AIS identification. Feature size
reduction of up to 60% through training set size reduction, however, maintained high performance
of the models.
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2.5.6 Calibration using an empirical function differentiates the models and may identify addi-
tional control sets.
We calibrated the output of the models so that the predicted probability could be meaningfully
interpreted (see Method 2.3.7). After recalibration, the AdaBoost classifier type, in particular,had
the lowest root mean squared error (RMSE) of probabilities predicted. AdaBoost models that were
trained with controls without cerebrovascular disease produced the lowest RMSE. This suggests
the need for a more stringent definition of controls than simply no AIS code diagnosis. AdaBoost
and logistic regression models trained on stroke service patients as cases and stroke mimics as
controls also performed well and showcases another important control set to consider. Some case-
control sets, namely stroke service cases with random patients as controls and cerebrovascular
disease without AIS codes as controls produced well-calibrated test sets before calibration by the
boot-strapped training set but poor calibration in testing. This suggests that our training set may
have over-weighted the importance of the controls. In addition, we evaluate the calibration perfor-
mance based on the RMSE of the calibrated test set, when in the future we would like to evaluate
based on the training set. Our study shows that calibration potential of each model may better
discriminate model success for studies with a large control:case ratio than traditional evaluation
methods such as AUROC.
2.5.7 Models can identify a large number of stroke patients without acute ischemic stroke diag-
nosis codes.
Our results from traditional model performance and robustness evaluations show that our best
machine learning phenotyping algorithm used Logistic Regression with L1 penalty or AdaBoost
classifiers trained with controls without any cerebrovascular disease-related codes and a stroke
service case population. However, we found that a similar model performed comparably well
using cases identified by AIS-related diagnosis codes, suggesting that these models do not require
manual case curation for high performance. In addition, our validation study in the UK Biobank
detected AIS patients without ICD10 codes up to 150-fold better than random selection.
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2.5.8 Limitations
This study has several limitations. First, we relied on noisy labels and proxies for training our
models, as evidenced by the false positive rate of 4-16% that was determined by manual review.
Without a gold standard set of cases, model performance is difficult to definitively evaluate. Sec-
ond, we used only structured features contained within standard terminologies across the patients’
entire timeline and did not use clinical notes. While clinical notes may contain much highly rele-
vant information, they may also give rise to less reproducible and generalizable feature sets. Ad-
ditionally, each feature contributed incrementally to high performance of the models and required
minimal processing to acquire. Third, due to limitations of time and computational complexity,
we did not exhaustively explore all possible combinations of cases and controls, including other
potential AIS mimetic diseases. Despite these limitations, precision in the internal validation using
the held-out set was high, and when applied to an external validation cohort, the developed models
improved detection of AIS patients between 60 and 150-fold over random patient identification.
Fourth, we did not study clinical implementation of the models. However, the discriminatory abil-
ity of the classifiers in the external validation suggest that although these models have not been
implemented clinically, they may potentially be useful for improving the power of existing clinical
and research study cohorts.
2.5.9 Strengths
Our study benefits from several strengths. First, to address the current deficiencies in develop-
ing phenotyping algorithms, we developed an approach that demonstrates comparable discrimina-
tory ability of identifying patients with AIS to past methods but has the added benefit of using EHR
data that is generally available during inpatient hospitalization. Second, our model features were
composed of structured data that encompass a larger feature variety than purely ICD-code based
algorithms. Third, because our model incorporated structured data from standard terminologies, it
may be generalizable to other health systems outside CUIMC, whereas recent studies have relied
on manually curated feature sets[77]. Fourth, we examined several different combinations of cases,
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controls and classifiers for the purposes of training phenotyping models. Finally, our phenotype
classifiers assign probability of having had an AIS, which moves beyond binary classification of
patients to develop a more granular description of patient’s disease state.
2.6 Conclusions and future directions
In addition to research tasks such as cohort identification, future models could focus on timely
interventions such as care planning prior to discharge and risk stratification. We showed that struc-
tured data may be sufficiently accurate for classification, allowing for widespread usability of the
algorithm. We also demonstrated the potential for using machine learning classifiers for cohort
identification, which achieve high performance with many features acquired through minimal pro-
cessing. In addition, patient cohorts derived using AIS diagnosis codes may obviate the need for
manually-curated cohorts of patients with AIS, and procedure codes may be useful in identifying
patients with AIS that may not have been coded with AIS-related diagnosis codes. Specifically, our
phenotyping model aims to place patients on a spectrum of being a stroke patient. The probabil-
ity represents patients along this spectrum including those with direct evidence of stroke, patients
who have predisposition to stroke but have not experienced the environmental trigger leading to
stroke, patients with some risk factors for stroke but have not had a stroke, and patients who have
very few to no risk factors for stroke and have not had a stroke. We, and others, hypothesize that
expanding cohort size by assigning a probability of disease may improve the power of heritability
and genome-wide association studies[107, 108, 109, 110, 111]. Utilizing the structured framework
present in many current EHRs, along with machine learning models, may provide a generalizable
approach for expanding research study cohort size.
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Figure 2.10: Classifier type with Stroke Service Cases, Stroke Mimetic Controls (SN) case-
control combination varies in calibration success between stroke score and actual proportion
of patients at each probability.
Figure 2.11: Classifier type with Stroke Service Cases, Controls without T-L codes for AIS
(SI) case-control combination varies in calibration success between stroke score and actual
proportion of patients at each probability.
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Figure 2.12: Classifier type with Stroke Service Cases, Controls with ICD9 or ICD10 codes
for CvD, and without T-L codes for AIS (SCI) case-control combination varies in calibration
success between stroke score and actual proportion of patients at each probability.
Figure 2.13: Classifier type with Stroke Service Cases, Random patients in the EHR as con-
trols (SR) case-control combination varies in calibration success between stroke score and
actual proportion of patients at each probability.
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Figure 2.14: Classifier type with Cases with T-L codes for AIS, Stroke Mimetic Controls
(TN) case-control combination varies in calibration success between stroke score and actual
proportion of patients at each probability.
Figure 2.15: Classifier type with Cases with T-L codes for AIS, Controls without T-L codes
for AIS (TI) case-control combination varies in calibration success between stroke score and
actual proportion of patients at each probability.
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Figure 2.16: Classifier type with Cases with T-L codes for AIS, Controls without ICD9 or
ICD10 codes for CvD (TC) case-control combination varies in calibration success between
stroke score and actual proportion of patients at each probability.
Figure 2.17: Classifier type with Cases with T-L codes for AIS, Controls with ICD9 or ICD10
codes for CvD, and without T-L codes for AIS (TCI) case-control combination varies in cali-
bration success between stroke score and actual proportion of patients at each probability.
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Figure 2.18: Classifier type with Cases with T-L codes for AIS, Random patients in the EHR
as controls (TR) case-control combination varies in calibration success between stroke score
and actual proportion of patients at each probability.
Figure 2.19: Classifier type with Cases with ICD9 or ICD10 codes for CvD, Stroke Mimetic
Controls (CN) case-control combination varies in calibration success between stroke score
and actual proportion of patients at each probability.
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Figure 2.20: Classifier type with Cases with ICD9 or ICD10 codes for CvD, Controls without
T-L codes for AIS (CI) case-control combination varies in calibration success between stroke
score and actual proportion of patients at each probability.
Figure 2.21: Classifier type with Cases with ICD9 or ICD10 codes for CvD, Controls without
ICD9 or ICD10 codes for CvD (CC) case-control combination varies in calibration success
between stroke score and actual proportion of patients at each probability.
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Figure 2.22: Classifier type with Cases with ICD9 or ICD10 codes for CvD, Controls with
ICD9 or ICD10 codes for CvD and without T-L codes for AIS (CCI) case-control combination
varies in calibration success between stroke score and actual proportion of patients at each
probability.
Figure 2.23: Classifier type with Cases with ICD9 or ICD10 codes for CvD, Random patients
in the EHR as controls (CR) case-control combination varies in calibration success between
stroke score and actual proportion of patients at each probability.
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Figure 2.24: Prevalence of features in cases vs controls in the TCI model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.25: Prevalence of features in cases vs controls in the TC model. Left to Right: LR,
RF, AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot
correlates with higher feature importance or beta coefficient weight, depending on the classifier
type. Gray dots are features with zero importance.
Figure 2.26: Prevalence of features in cases vs controls in the TI model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance
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Figure 2.27: Prevalence of features in cases vs controls in the TR model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.28: Prevalence of features in cases vs controls in the TN model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.29: Prevalence of features in cases vs controls in the CR model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
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Figure 2.30: Prevalence of features in cases vs controls in the CC model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.31: Prevalence of features in cases vs controls in the CI model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.32: Prevalence of features in cases vs controls in the CCI model. Left to Right: LR,
RF, AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
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Figure 2.33: Prevalence of features in cases vs controls in the CN model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.34: Prevalence of features in cases vs controls in the SN model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.35: Prevalence of features in cases vs controls in the SCI model. Left to Right: LR,
RF, AB, GB, and EN models.Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
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Figure 2.36: Prevalence of features in cases vs controls in the SC model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.37: Prevalence of features in cases vs controls in the SI model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
Figure 2.38: Prevalence of features in cases vs controls in the SR model. Left to Right: LR, RF,
AB, GB, and EN models. Axes are on a logarithmic scale. Increasing size of blue dot correlates
with higher feature importance or beta coefficient weight, depending on the classifier type. Gray
dots are features with zero importance.
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Chapter 3: Data-driven subtyping of acute ischemic stroke
3.1 Introduction
Although genome-wide association studies have uncovered many variants for a wide range of
diseases, many still have a high proportion of missing heritability[17, 15, 113, 114]. This lost ge-
netic signal may be due to phenotype heterogeneity[17]. In addition, the largest GWAS for stroke
and its ischemic stroke subtypes found only thirty-two significant loci after carefully phenotyping
each patient[11, 8, 9, 115]. This number of variants is much smaller than those found in other
common diseases. This is partially due to the genetic heterogeneity of the disease across subtypes,
which hinders the discovery of causative variants[9]. Accurate determination of the etiology of
stroke is essential for genetic studies, in addition to risk stratification, optimal treatment, and pre-
diction of outcomes. This can be difficult, however, because, as described in Chapter 1, there is
a wide range of causes of stroke, with up to 40% labeled undetermined by traditional methods of
subtyping[8, 6, 7, 4]. This highlights the need for a data-driven approach to subtyping in order to
uncover the etiologies of strokes of unknown cause and patterns of distinct combinations of envi-
ronmental and genetic risk factors leading to stroke. Traditionally, the Trial of Org 10172 Acute
Stroke Treatment (TOAST) criteria is used to subtype ischemic stroke into the following cate-
gories: large artery atherosclerotic stroke, small artery lacunar stroke, cardioembolic stroke, stroke
of other determined cause, and stroke of unknown cause[116]. These traditional criteria, however,
have not been granular enough for treatment decisions. The ASCO (Atherosclerosis, Small ves-
sel disease, Cardiac source, and Other) criteria provide percentages of evidence for each subtype
without choosing the most probable cause[117]. The Causative Classification System (CCS1) for
stroke provides a comprehensive algorithm combining medical and family history, demographics,
imaging, and labs to determine the most likely cause of the stroke. It assigns patients multiple
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pathogenic mechanisms based on their clinical picture and is currently found to be the most sen-
sitive subtyping system[118, 119]. This classification method, however, is time consuming, since
it requires a trained researcher to manually classify the patients[118]. We hypothesize that divid-
ing ischemic stroke patients into more specific groups based on their clinical picture can provide
data-driven insight into the causes of the disease, predict cohorts more likely to have recurrence or
serious morbidity, and group people who are more likely to share similar gene variants.
Although the electronic health record (EHR) provides a rich amount of information about the
medical history of each patient, identifying subtypes within the EHR is challenging because of
the sparsity of the data, its ascertainment bias, and its optimization for insurance billing rather
than research. Patients only interact with the EHR when sick or for a wellness check up, and
which leads to a discontinuous and incomplete medical timeline[26, 44]. In addition, structured
data is recorded primarily for medical communication and insurance billing purposes, so it is not
optimized for research purposes[26, 72]. As seen in Table 3.1, the vast majority of cases are solely
described as cerebral infarction due to unspecified cause. More information, such as risk factors,
prior treatments, and procedures must be curated from the EHR to determine the subtype of stroke.
In addition, optimal subtyping techniques need to take into account the sparsity and missingness
of the data.
Factorization methods, such as non-negative matrix factorization (NMF), have been shown to
identify interpretable latent topics, or subtypes, in text better than PCA or vector quantization[61].
NMF has successfully subtyped type 2 diabetes mellitus, hypertension and cardiovascular disease,
but has not been applied to stroke[57, 58, 59, 60]. A limitation of NMF is that it can over-inflate the
importance of missing data, not taking into account the false negative[65]. In addition, Bayesian
factorization methods such as hierarchical Poisson factorization is well-suited for identifying sub-
types of patients in the EHR. Similar to previous uses of the method in RNA-seq or click data, item
use is sparse, there are some patients who are in the system much more frequently than others, and
data are missing not-at random[65, 64]. We can apply these methods to identify groups, or topics,
of risk factors before a stroke that may predict outcomes after the stroke. Deep learning methods
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Table 3.1: Distribution of AIS subtypes using only AIS ICD9 or ICD10 codes
such as denoising autoencoders, as described in Chapter 1 also have been successful in subtyping
disease, but interpretation and implementation can be difficult. In this study, we apply NMF and
HPF to structured EHR data to identify topics of clinical features found in patients before their first
acute ischemic stroke that are significant for predicting stroke severity.
3.2 Methods
Data extracted from the Columbia University Irving Medical Center (CUIMC) Clinical Data
Warehouse (CDW) contained longitudinal health records of 6.4 million patients spanning from
1985-2018. We selected 4,386 patients with acute ischemic stroke (AIS) evaluated on the stroke
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service at New York Presbyterian Hospital. We gathered diagnostic and procedure International
Classification of Diseases (ICD) codes, medication prescriptions, race/ethnicity, age, and gender
of each patient. AIS was defined by diagnosis codes within the Tirschwell-Longstreth criteria[24].
To study risk factors leading to the AIS, we only extracted data before the patient’s first recorded
stroke. We also manually extracted the National Institute of Health Stroke Severity Score from
the unstructured medical notes of 488 of the patients seen on the stroke service for their AIS as a
measure of severity. We used data structured in the OMOP CDM format in the EHR because this
data is more easily accessible and reproducible at other hospitals, and requires little processing
power compared to parsing notes from the EHR[36]. We ran non-negative matrix factorization
of data from all 4,386 stroke patients before their first acute ischemic stroke. In order to reduce
sparsity, we trained the model on features seen in at least 20 patients, which reduced the feature
size from 14,618 to 2,264. In NMF, the patient by feature matrix (X) is factorized into a topic by
feature matrix (H) and patient by topic (W) matrix. In H, each feature is assigned a weighting to
every topic, and in W, every patient is assigned a weighting to every topic. We implemented the
NMF module in the scikit-learn python package. We set the number of components, or topics, to
20, calculated loss by kullback-leibler distance, penalized the model with an even ratio of l1 and
l2, and ran for 1000 iterations.
We then compared the non-negative matrix factorization method to a probabilistic method,
hierarchical Poisson factorization (HPF). We implemented scHPF created by [65] and found at
https://www.github.com/simslab/scHPF/tree/master. In our implementation, cells replaced patients,
and structured medical data of the patients replaced genes. Patient scores for each factor and fea-
ture scores for each factor were calculated by sampling the product of variational distributions of
latent variables from the model. We used the default settings for the hyperparameters. As seen
in [65], the posterior probability of the model was inferred using Coordinate Ascent Variational
Inference. Hyperparameters b′ and d′ were calculated empirically based on the ratio of mean to
variance of items per patient or per medical feature, a′ and c′ were set to 1 and a and c were set to
0.3, and variational parameters ξ, β,θ, and η were sampled from gamma distributions whose rate
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(a) Poisson Log-Likelihood vs. HPF run (b) Mean Log-likelihood vs. Number of factors number
Figure 3.1: (a) Poisson Log-Likelihood vs. Iteration for HPF shows convergence, k=100. (b)
Mean Log-Likelihood vs. factor k size
and shape were randomly initialized between 0.5 and 1.5 times its prior[65].
We ran the model for 7 different factor size k: 20, 30, 40, 50, 80, 100, and 130. Figure
3.1a shows a sample convergence of the model at k=100, and Figure 3.1b shows increased log-
likelihood with increasing k size.
We ran the model 5 times with random initialization until the drop in loss was less than 0.001
percent, 1000 iterations were run, or the loss increased, whichever came first.
3.2.1 Determining stability of the topics
To determine the stability of the topics, we calculated the Tanimoto coefficient of the top 20
features between every topic between every NMF and HPF run (n=100 runs, 8 runs respectively).
3.2.2 Using topics to predict stroke severity
Because of the instability of the HPF topics, we only used NMF topics for severity analysis.
For the 488 patients with stroke severity scores, we randomly divided the patients into 300 training
cases and 188 testing cases. We then ran a univariate linear regression on each topic from NMF
with stroke severity as the outcome. After correction by false discovery rate, we predicted the
stroke severity of the test patient cases.
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3.3 Results
3.3.1 Non-negative matrix factorization and hierarchical Poisson factorization topics
Each patient was assigned to the topic with their maximum W component found using NMF.
Table 3.2 shows the top 10 scoring medical features for each factor. The maximum weight for
33% of patients was on a topic with general demographics such as white race, gender, age and
lymphoma and colon cancer. The next largest proportion, 7.5% of patients, had maximum weight
for the topic with essential hypertension, pure hypercholesterolemia, and osteoarthritis as its top
three features, and 6.7% of patients had maximum weight for the topic with atrial fibrillation,
essential hypertension, and aortic valve disorder as its top three features.
In comparison, as seen in Table 3.3, hierarchical Poisson factorization displayed more special-
ized topics, only covering 1-3 different disease processes and with no generalized hospitalization
or procedure topics as seen using NMF. Topic 6 had the highest proportion of patient maximum
scores, 26%, whose top scoring features included cancers and pregnancy. This group of patients
were enriched for internal carotid artery dissection, acetaminophen, laxative, and vertebral artery
dissection after stroke diagnosis. The next most common topic, 19, with 9% of patients included
topics of joint disease and Parkinson’s disease. These patients were enriched for procedures of the
elderly including shingles vaccine administration, hearing aid fitting, ear wax removal, and physi-
cal therapy after stroke diagnosis. In general, for HPF, the enrichment of features in patients after
stroke were similar to the disease processes of top scoring features of each factor.
Figure 3.2 shows hierarchical clustering maps of patient scores across all topics for NMF and
HPF. As seen in the figure, NMF assigns smaller weights to most factors for each patient compared
to the patient scores sampled from the HPF model. The HPF model appears to identify clearer
clusters of patients compared to NMF.
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Table 3.2: Top ten features found from structured medical data from 4,368 AIS patients
before their first recorded stroke using Non-negative Matrix Factorization, number of com-
ponents=20
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Table 3.3: Top ten features found from structured medical data from 4,368 AIS patients
before their first recorded stroke using hierarchical Poisson factorization, number of compo-
nents=20
3.3.2 NMF topics are stable
The NMF topics were more stable than HPF topics. Out of the expected NMF topic matches,
98% had a Tanimoto coefficient of 1. Out of the expected HPF topic matches, 24% had a Tanimoto
coefficient above 0.5.
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Figure 3.2: Hierarchical Clustering of Patient Scores for each factor, K=20, Left= NMF,
Right=HPF
3.3.3 Topics were significantly correlated with stroke severity
After running a univariate linear regression for each topic on different randomized training
samples of 300 patients with stroke severity scores, we found four topics significantly correlated
with stroke severity in at least one run. Table 3.4 shows the performance of the four topics on
predicting stroke severity in the test set. The average stroke severity score in the test set was
8.85 ± 8.71. The topic with atrial fibrillation as its highest weighted feature was significantly
correlated with severity for 35% of the trials with the lowest p-value of 2.3E-05, and its top features
included valve disorders, essential hypertension, warfarin, atrial flutter, metoprolol, and high risk
drug monitoring status. The patients highest weighted for this topic had the highest average NIHSS
score of 12.1 ± 10.9. The topic with type 2 diabetes mellitus as its highest weighted feature was
significantly correlated with severity in 5% of the trials with the lowest p-value of 0.0012, and its
top features included type 1 diabetes mellitus, ECG and medications for diabetes. The patients
highest weighted for this topic had an average NIHSS score of 8.53 ± 7.10. The topic with a
chest x-ray as its highest weighted feature was significantly correlated with severity in 2% of the
trials with the lowest p-value of 0.0088, and its top features included critically ill patient, pleural
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effusion, abnormal breath sounds, ECG, atelectasis, medical decision making of high complexity,
pneumonia, and acute respiratory failure. The patients highest weighted for this topic had the
second highest average NIHSS score of 11.4 ± 7.87. The final significantly correlated topic with
AIS, in 2% of the trials and with a lowest p-value 0.043, had age as its highest weighted feature,
























35% 5% 2% 2%
Mean absolute
error
6.6 ± 0.21 6.7 ± 0.14 7.1 ± 0.21 7.1 ± 0.18
Root mean
squared error
8.2 ± 0.32 8.3 ± 0.20 9.3 ± 0.29 8.9 ± 0.26
Mean NIHSS 12 ± 10 9.8 ± 10 8.5 ± 7.7 11 ± 7.9
Table 3.4: Topics derived from Non-negative matrix factorization significantly correlated
with stroke severity
3.4 Discussion
Subtyping using factorization methods produced topics enriched for important risk factors be-
fore the patients’ first acute ischemic stroke. Non-negative matrix factorization topics were more
stable compared to HPF topics, and several were significantly correlated with stroke severity. The
topic with the most significant runs also had patients with the highest mean severity score. The
top weighted feature in this topic was atrial fibrillation, which is associated with more severe
strokes[120]. The mean absolute error of the severity predictions was between 6.6-7.2, which is
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smaller than the difference between mild and severe strokes on the NIHSS scale (10-30 points).
This topic also represents a traditional TOAST subtype of acute ischemic stroke, cardio-embolic
stroke. Other topics that correlated with severity represented more granular etiologies of stroke
than those found using the TOAST subtype. One included a top weighted feature of diabetes melli-
tus 2, a known risk factor for stroke[5]. In addition, a third topic included highly weighted features
such as acute respiratory failure and pneumonia. Respiratory infections such as influenza have
been shown to trigger cardiovascular events such as myocardial infarction[121] and stroke[122, 5].
3.4.1 Limitations
This study had several limitations. We did not complete hyperparameter tuning for the HPF
model, which could be a reason why the HPF model topics had low stability across runs. Each
HPF run had a long run time, making the NMF model more feasible. In addition, at up to 120
topics, the HPF mean log-likelihood had not plateaued, suggesting that more topics are needed for
greater stability. Such a large number of topics however, does not translate to feasible subtypes for
acute ischemic stroke. In addition, although the NMF topics were stable, the most common topic
was a general demographics and cancer topic. Although the general demographic features of the
topic were non-specific, cancer is a risk factor for stroke[123]. In addition, other topics that did
correlate with severity, such as patients with acute respiratory distress and pneumonia and those
with atrial fibrillation represent important AIS patient subsets. Finally, we did not determine the
genetic heterogenity of the subjects within the subtypes, which would require a larger sample size
and future study.
3.5 Conclusions
This study implemented non-negative matrix factorization (NMF) and hierarchical Poisson
factorization (HPF) to identify groups of risk factors within patients that predict acute ischemic
stroke severity. Both NMF and HPF identified subgroups of patients with specific disease pro-
cesses, though NMF topics were preserved across runs more stably than HPF topics. Factorization
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approaches to analyze data available in the EHR can identify previously unrecognized ischemic
stroke subtypes, unbiased by clinical preconceptions of etiology. Such subtypes correlate with
stroke severity and include conventionally recognized clusters, such as stroke associated with atrial
fibrillation and other cardiac diseases, but also novel subtype clusters, such as stroke associated
with respiratory failure and pneumonia. Future directions include improving the stability of topics
within the HPF models, studying other neuro-psychological sequelae of stroke, and incorporating
unstructured notes into this model to improve the richness of the data. A semi-supervised approach
of projecting factors from the models on physician-subtyped patients may provide a link between
the data-derived factors and clinically meaningful AIS subtypes such as those defined by TOAST
and ASCO[63, 116, 117]. Finally, we would like to test whether these more granular topics sep-
arate stroke patients into less genetically heterogeneous subtypes by estimation of heritability of
each subtype using RIFTEHR and solarSTRAP (discussed in Chapters 4 and 5).
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Chapter 4: Expansion of Case/Control cohorts by application of machine
learning models to the EHR: Applications to heritability and genetics within
Columbia and the eMERGE dataset
4.1 Introduction
Large genetic repositories connected to electronic health records (EHR) form the basis of local
and national precision medicine initiatives. These linked repositories promise the ability to perform
thousands of simultaneous genetic studies using diagnoses, procedures, and treatment responses
that are routinely captured by the EHR. Not all patients have genetic data available, however,
limiting what actually can be studied. There is opportunity to use machine learning methods to
derive quantitative proxy variables and expand the sample population. We hypothesized that the
output of a supervised machine learning classifier can be used as a proxy variable for disease
classification and be an efficient strategy for expanding a study cohort. We tested this hypothesis
in two genetics studies that would benefit from cohort expansion: heritability estimation and a
genome-wide association study.
Heritability, often measured through family studies, provides a quantitative measure for the
genetic component of a disease[15]. Conducting family or genome-wide association studies for
every disease is a time-consuming and expensive process; therefore, a systematic manner to iden-
tify diseases with a genetic component is needed. Polubriaginof et al. developed a high- through-
put corollary to the genetic estimate of heritability, termed observational heritability[51]. Without
genetic data, they suggested which diseases are heritable and should be studied genetically. In
contrast to traditional estimation of heritability, observational heritability is measured using fam-
ilies derived from the EHR. These families were extracted using an algorithm, RIFTEHR, which
uses emergency contact information to infer familial relationships between patients at the hospi-
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tal[51]. They found and inferred relationships within 223,307 families and estimated heritability
using a bootstrapped version of SOLAR (SOLARstrap), a program that uses identity by descent
calculations to estimate trait heritability from pedigrees[51, 124]. They were able to estimate the
heritability of over 500 diseases, though they attempted to estimate 2500 disease heritabilities.
Since the acquisition of disease case/control status was from patient electronic health records, this
heritability analysis is not structured like a tradition genetic study, in which there is a proband and
search for family members with or without the disease[51, 124]. Only family members that interact
with the hospital system have a disease status, which leads to an ascertainment bias and a reduced
cohort size[51, 124, 26]. Phenotyping may also have affected the success of disease heritability
estimation. Each case was phenotyped by a single ICD9 code for the disease, and each control
did not have the ICD9 code for the disease or any disease code within the same Clinical Classi-
fication System category[98]. Acute ischemic stroke heritability, for example, was not able to be
estimated by RIFTEHR and SOLARstrap. As demonstrated in Chapter 2, single diagnosis codes
for disease may not be enough to identify all cases, and it is not clear whether patients without a
stroke diagnosis can be considered a control. Similarly, it is difficult to determine whether fam-
ily members with only cerebrovascular disease or metabolic disease should be considered controls
since there is significant enrichment of genetic variants from coronary artery disease, hypertension,
and atrial fibrillation in stroke patients[125]. Therefore, we hypothesized that heritability estimates
could benefit from assigning patients on a spectrum of disease from 0 to 1. Specifically, instead of
treating stroke as a dichotomous trait, we converted it to a quantitative one– the probability that a
patient had an acute stroke.
Genome-wide association studies move beyond the family linked studies to identify common
variants affecting complex traits. Ischemic stroke, in particular, has a high heritability estimate,
37.9% ± 5.2%, and the most recent GWAS identified over 20 associated variants[10, 11]. To
achieve adequate power, this study required over 40,000 cases and 520,000 participants overall.
These cohort sizes, with genetic data, are generally only achievable through large meta-analyses.
We hypothesized that our cohort expansion method could improve the power of genome-wide as-
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sociation studies with a fraction of those cases. We tested this hypothesis on a disease with a
validated phenotyping algorithm applied to a small number of cases within a large dataset. The
Electronic Medical Records and Genomics (eMERGE) consortium developed a database of rule-
based algorithms, PheKB, to identify cases and controls of dozens of phenotypes [34, 126]. The
algorithms are designed by physicians and bioinformaticians and validated at one or more major
medical centers with a positive predictive value of at least 90%. The algorithms vary in computa-
tional complexity, from extracting diagnosis and procedure billing codes and lab values to applying
natural language processing to medical notes. In addition, the phenotypes are validated within the
eMERGE consortium, which consists of subjects across nine study sites in the US. As a proof of
concept that the conversion of dichotomous to quantitative traits can identify variants of a disease,
we implemented a phenotype that was well characterized in PheKB, venous thromboembolism
(VTE). To demonstrate the utility of this quantitative trait proxy in a genetics study, we trained
classifiers on algorithmically phenotyped cases and controls of venous thromboembolism (VTE)
using EHR-extracted features. We then tested the classifiers on VTE cases and controls in the
EHR with genotyping data. Finally, to better understand the effect of converting a binary trait to
quantitative on power, we simulated a complex trait. We used an additive model, as suggested
through previous studies, as the mode of inheritance of causal traits [127], and varied the effect
sizes, penetrance, and allele frequencies.
In our heritability estimation study, we show that our stroke phenotyping models can estimate
stroke heritability, while traditional binary classification of stroke could not. In our genome-wide
association study of venous thromboembolism in the Columbia eMERGE cohort, we were under-
powered to recover variants. Our simulation studies, however, suggest that power may be mini-
mally improved by converting binary traits to quantitative ones.
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4.2 Methods
4.2.1 Estimating heritability in stroke with phenotyping model probabilities
We applied the probabilities generated from our phenotyping models to estimate the heritabil-
ity of stroke without genetic data (Figure 4.1). We ran SOLARstrap against the model probabil-
ities identified from each case-control and classifier model. For every model, we estimated the
heritability 200 times, sampling 2000 families for each run. This bootstrapping method reduces
ascertainment bias in the heritability estimation. If we were to estimate the heritability using all
families available in the EHR, the estimate would be influenced by the most complete families with
the disease in the EHR. By bootstrapping the families, we reduce inflated heritability estimation,
as shown in [51]. We compared heritability estimates with and without taking into account shared
environment within households. Finally, we compared the number of SOLARstrap runs that suc-
cessfully converged using the original model probabilities to the number of runs that converged
after multiplying the probabilities by 100.
Figure 4.1: Schematic of Stroke Model Training and Application to heritability estimation.
Cases:1) Physician curated, gold standard stroke patients (G), 2) Patients with stroke insurance
billing codes (I), 3) Patients with cerebrovascular disease billing codes (C) Controls: 1) Stroke
mimetic neurological diseases (N), 2,3) Sample of patients in EHR without stroke code (I,S), 4)
Sample of patients in EHR without cerebrovascular disease codes (C), 5) Sample of patients in
EHR with cerebrovascular disease codes but without stroke codes or not gold standard (CI) 6) Ran-
dom sample in EHR (R). Case:Control ratio was between 1:1 and 1:2, models included Random
Forest (RF), Logistic Regression (LR), Neural Network (NN), Gradient Boosting (GB), Elastic
Net (EN) and Adaboost (AB).
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4.2.2 Venous Thromboembolism Phenotyping Model Development
From the Columbia group of the eMERGE consortium, we received 3,071 patients’ MRNs
linked to the New York Presbyterian Hospital EHR. Given the small number of patients and the
low effect sizes of known stroke variants, we did not use stroke as our test disease[11]. We in-
stead chose a disease with a rule-based phenotyping algorithm from the PheKB database due to
the PheKB algorithms’ high positive predictive value and reproducibility across institutes[126].
Seven of the eMERGE PheKB algorithms were applied to the Columbia eMERGE group patients:
venous thromboembolism, chronic kidney disease, colorectal cancer, autism, rheumatoid arthritis,
type II diabetes, and heart failure. Because of the small sample size of patients, we filtered for
diseases with known associated variants with an odds ratio of greater than 2 using the EBI-GWAS
catalog and the largest number of cases[128]. Chronic kidney disease had the most cases, 2231,
but only 288 controls, which would have lead to a large case/control imbalance. We chose venous
thromboembolism (VTE), which is a thrombotic disease and a leading cause of cardiovascular
death[129, 130]. It is often caused by commonly inherited variants leading to a hypercoaguable
state[129]. The disease has 5 high effect size variants, increasing the chance of recovery through
GWAS[131, 130, 33, 129, 132]. The algorithm was developed at the Mayo Clinic and had 100%
positive predictive value and 95% negative predictive value at their institute[133]. When applied
to the Columbia eMERGE dataset, the algorithm assigned 419 as cases for VTE, 2,551 as controls,
and 101 as undetermined. We collected genotyping data on 2,065 subjects, 1058 of which were
male, and 1007 female. (VTE cases, n=289, controls, n=1721) We then trained several machine
learning models on the patients without genetic data and with a definite case-control label (VTE
cases, n=130, controls, n=830). From the EHR, we pulled conditions, procedures, drugs, and all
demographics of each patient, assigning each as a binary presence or absence of the feature to each
patient. Age was also treated as a binary variable, where greater than 50 was considered 1. We
trained logistic regression models with L1 (LR) and elastic net (EN) penalties, a random forest
(RF) model, gradient boosting (GB) model, adaboost (AB) model, and a neural network (NN) on
the 960 patients without genotyping data, evaluating with 10-fold cross validation. Hyperparame-
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ters were the same as described in Method 2.3.5. In addition, we compared the performance of 1)
using feature counts instead of binary presence or absence of each feature, and 2) only including
features with 2 or more counts in the model. We then tested the original binary feature models on
the patients with genetic data.
Figure 4.2: Schematic of Model Training and Application in GWAS. Cases: eMERGE Venous
Thromboembolism cases without genetic data, Controls: eMERGE Venous Thromboembolism
controls without genetic data. Models included Random Forest (RF), Logistic Regression (LR),
Neural Network (NN), Gradient Boosting (GB), Elastic Net (EN) and Adaboost (AB) and are
trained on structured medical data and applied to 2,062 patients with genotyping data. Quantitative
trait GWAS using the model probabilities for the patients was then run.
4.2.3 VTE GWAS implementation
After assigning model probabilities for VTE for Columbia eMERGE subjects with genetic data,
we ran genome-wide association studies. The genotyping data was imputed by the University of
Michigan Imputation Server (MIS) using the Haplotype Reference Consortium (HRC1.1) in build
37[35]. Quality control on the genotyping data conducted by Dr. Anna Basile included filtering for
SNPs with a minor allele frequency of greater than 1%, Hardy-Weinberg equilibrium test p-value >
10−10, and imputation INFO scores of greater than 0.3. She then ran linkage disequilibrium pruning
on the variants with an r2 threshold of 0.7 and PCA analysis. The top five principal components
explained over 98% of the variance, so we used these 5 PCs as covariates in addition to sex,
age, incidence of stroke, and incidence of myocardial infarction. We ran a Mann-Whitney U test
comparing the cases and controls for each covariate and found significant differences for all except
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for PCs 2, 4, and 5. We removed these PCs from the covariates. We then ran a logistic regression
GWAS on the 2,062 patients using Plink, where cases and controls were identified from the PheKB
algorithm[134]. We then ran four linear regression genome-wide association studies on the same
patients’ genotyping data using different quantitative phenotypes: 1) the model probabilities from
the neural network (NN) model, 2) model probabilities from the random forest (RF) model, and 3)
and 4), the log base 10 of the NN and RF model probabilities. We chose the RF model since it gave
the best performance (see Result 4.3.2) and the NN model since its model probabilities were the
most normally distributed. We also compared the log base 10 probabilities since their distributions
were more normal. We determined whether the known VTE variants were recovered by the binary
or quantitative studies by first converting the known VTE variants from the EBI-GWAS database
to chromosome positions from the chr38:12 build to the chr37.p13 build[128]. The genetic data
was imputed by the University of Michigan, and we were given chr:bp as variant identifiers rather
than SNP name. We mapped the variants using the NCBI Genome Remapping Service[135].
4.3 Results
4.3.1 Heritability estimates using the models as quantitative traits
Using the model probabilities from our phenotyping models, we estimated the observational
heritability of acute ischemic stroke to be 0.16-0.28, depending on the model used. We used a
cutoff of at least 30/200 converging runs and a Proportion of Significant Attempts (POSA) score
of 0.7. As shown in Polubriaginof et. al, the POSA score measures the proportion of converged
runs that are statistically significant. The more runs that converged and are statistically significant,
the more representative the heritability of all samples. Adjusting by household effect reduced the
heritability estimates by an average of 6.2%. Random Forest models had the most case-control
sets successfully estimate heritability (12/15). All other classifier types increased the proportion of
successful heritability estimates among case-control sets (LR from 6/15 to 7/15, AB from 1/15 to
7/15, GB from 4/15 to 11/15, and EN, from 7/15 to 8/15) by multiplying the model probabilities by
100. Though the number of successful estimates increased, mean values did not change apprecia-
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bly, with an increase of 0.1-0.2%. The RF models estimated the highest mean heritability for acute
ischemic stroke, 0.27±0.090, LR had a mean heritability estimate of 0.17±0.053, AB, 0.22±0.08,
GB, 0.23±0.053, and EN, 0.21±0.081 The TCI case-control set successfully estimated heritability
across all classifier types. The CC case-control set with random forest or adaboost classifier had
the highest heritability estimates of 0.38± 0.04. The TI, TC, and CI case-control sets with random
forest classifier also had high heritability estimates of 0.34 ± 0.04, 0.34 ± 0.04 and 0.36 ± 0.04
respectively. The SCI and CCI case-control sets had the lowest mean heritability estimates of
0.12 ± 0.013 and 0.12 ± 0.015 respectively. Figure 4.3a shows the observational heritability es-
timates compared to model area under the receiver operating curve, and figure 4.3b shows the
estimates compared to area under the precision-recall curve. Neither shows an appreciable rela-
tionship between heritability estimates and performance. However, some high performing random
forest and adaboost models have heritability estimates within the literature heritability estimate
range for acute ischemic stroke. The curated case (S) models had the lowest average heritability
estimates 0.20 ± 0.08, followed by the CCS cerebrovascular disease case models (C), 0.24 ± 0.09,
and finally the AIS diagnosis code cases (T) 0.25 ± 0.07. The no ischemic stroke diagnosis code
controls models had the highest heritability estimates (0.28± 0.059) followed by the no CCS cere-
brovascular disease control models (0.26 ± 0.097). The N and CI control models had the lowest
heritability estimates (0.18 ± 0.033, 0.18 ± 0.070 respectively) and the random R control models
had a mean heritability estimate of 0.22 ± 0.070. Overall, our average heritability estimates were
36% lower than the literature estimate of 0.379 ± 0.052.
4.3.2 Performance of the VTE Phenotyping Algorithms
Cross-validation performance: The random forest model had the highest performance with an
AUROC of 0.84, area under the precision-recall curve (AUPRC) was 0.54 and maximum F1 score
was 0.51. The LR model had an AUROC of 0.82 and AUPRC of 0.48, AB model had an AUROC
of 0.79 and AUPRC of 0.47, EN model had an AUROC of 0.77 and AUPRC of 0.47, GB had an
AUROC of 0.71 and AUPRC of 0.40, and NN model had an AUROC of 0.79 and AUPRC of 0.41.
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(a) Observational heritability vs. AUROC (b) Observational heritability vs AUPRC
Figure 4.3: Observational heritability estimates versus phenotyping model performance. (a)
shows the observational heritability estimates versus area under the receiver operating curve (AU-
ROC) and literature heritability (h2) range (b) shows the observational heritability estimates versus
area under the receiver precision-recall curve (AUPRC) and literature heritability (h2) range
Changing the features from binary to counts or only using features with 2 or more counts resulted
on average in only a small (0.01-0.02) drop in AUROC.
4.3.3 Genome-wide association study for VTE
We were unable to recover any known VTE variants to nominal 0.05 significance in the binary
or the quantitative GWAS. We also were unable to find any variants with genome-wide signif-
icance. Only 59 out of 129 known VTE variants were found in the eMERGE genotyping array,
which had 6.8 million variants. A Mann-Whitney U test of the ranks of the VTE variants by P-value
compared to the other variants showed an AUROC of 0.6 for the binary trait GWAS, and 0.575 for
the quantitative trait GWAS using the log probability of the random forest model. Logarithm of
the p-values of the binary trait GWAS results were minimally correlated with the quantitative trait
results with an r2 of 0.30.
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4.3.4 Simulation of traits
The quantitative VTE score represents a probability of a patient’s classification as a VTE patient
based off their medical history. The probability is derived from a model trained on the EHR-derived
medical history of PheKB determined cases and controls. We were unable to rediscover the known
VTE variants using binary or quantitative traits, most likely due to a relatively small sample size.
To further test whether quantitative traits could recover variants as well as binary traits, we ran a
simulation on a single variant (Figure 4.4). We tested whether quantitative traits would be more
robust to phenotyping noise than binary traits. We created a sample of 10,000 patients, with a minor
allele frequency of 0.1, penetrance of 0.3 of the variant leading to disease, and general population
disease risk of 0.05. We then randomly assigned patients both variant and disease status based on
the rates described above. We then added noise at levels between .025 and .5 to the disease labels
and calculated the odds ratios and p-values of the variant effect size using a Fisher’s exact test.
We simulated 100 binary features for each patient, and assigned the features randomly at rates
between 0-1 for patients with the variant and between 0-0.5 for patients without the variant. We in-
clude a wider range of feature assignment rates for those with the variant because we imagine there
would be specific tell tale features, such as a medication or a condition that may more commonly
be seen in the patients with the variants. We then trained a random forest classifier on 75% of
patients and their 100 features to predict the remaining patients’ disease status. We then fit a linear
regression on the disease probabilities assigned by the model to variant status for each patient and
extracted the beta coefficient and p-value. We then swapped the disease labels of the training set
at different noise rates between 0.025-0.5. We again predicted on the remaining 25%, fit a linear
regression to the disease probabilities identified by the model to determine variant status of each
patient, and extracted the beta coefficients and their p-values.
4.3.5 Simulation of traits results
We found that penetrance of the variant was directly proportional to the performance of the
classifier (Figure 4.5A). We also found that increased noise was inversely proportional to the per-
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Figure 4.4: Schematic of Disease-Trait Power Simulation
formance of the classifier (Figure 4.5B). Within the binary trait simulation results, we found that
a penetrance of 0.3 gave an odds ratio of 8.1, and so used this value for the rest of the simula-
tions. We found that for the binary trait simulation, as noise increased, the odds ratio decreased
towards 1 as did the standard error. P values also were very low at low noise and moved towards
insignificant with noise at rates of 40% and 50% (Figure 4.5C). For the quantitative simulation,
the p value also increased towards insignificant at a rate of 0.5, and was lower than the binary trait
p values at all noise levels. Although converted odds ratios from the beta coefficients of the linear
regression using the quantitative trait were lower than the binary trait odds ratio, both held genome
wide significance until a noise rate of 50%.
4.4 Discussion
4.4.1 The models can estimate observational heritability at a lower average value than the litera-
ture estimate.
In Chapter 2, we developed a method to create a probability of disease for the acute ischemic
stroke phenotype. The RIFTEHR and SOLARstrap methods in Polubriaginof et. al. estimated the
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Figure 4.5: Results of Simulation Study, Varying Penetrance and Noise. (A) Area Under the
Receiver Operating Curve (AUROC) vs. Penetrance for simulated quantitative trait, (B) Area
Under the Receiver Operating Curve (AUROC) vs. Noise for simulated quantitative trait. Orange
represents results from noise only in training labels while blue represents results from noise in both
the training labels and feature assignment. (C) Log base 10 of P value versus Noise. Red triangles
represent the binary trait p-values, orange circles represent results from noise only in training labels
while blue circles represent results from noise in both the training labels and feature assignment.
heritability of over 500 diseases using only EHR data. For over 2000 diseases, however, including
stroke, the methods were unable to estimate heritability. We hypothesized that our models could
recover some of these heritability estimates by expanding case/control assignment to a probabil-
ity of disease and subsequently converting the binary trait to a quantitative one. For many of our
models, especially those using random forest classifiers, the RIFTEHR and SOLARstrap methods
successfully converged. The average heritability estimate was 36% lower than the known heri-
tability estimate. In general, RIFTEHR and SOLARstrap estimate heritabilities 20% lower than
the literature values[51]. Our models’ heritability estimates were lower and did not appear to have
a correlation between performance and heritability estimate. Some high performing random forest
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and adaboost models did estimate heritability within the literature range. In addition, the CCS
cerebrovascular disease (C) or ischemic stroke diagnosis code (I) cases and no cerebrovascular
disease or no ischemic stroke controls had the highest heritability estimates overall. This suggests
that expanding the case set by training on CCS cerebrovascular disease classifications or diagnosis
codes for stroke captured the disease heritability across families more successfully than training
on a curated data set. Although further study is needed to optimize the use of model probabili-
ties to convert binary to quantitative traits, we show that we can recover observational heritability
estimates for initially under-powered phenotypes, such as acute ischemic stroke.
4.4.2 Genome-wide association studies of venous thromboembolism were underpowered in the
Columbia eMERGE dataset.
Our study was underpowered to discover genome-wide significant VTE variants using either
traditional binary phenotyping or model probability phenotyping. All prior VTE GWAS studies
had at least 1,500 cases of European ancestry or 400 cases of African ancestry, while our study only
had 289 cases, half of which were African ancestry and the other half European. Although venous
thromboembolism has known variants with high odds ratios, we were unable to recover these vari-
ants to nominal significance. Simulated trait studies suggest that conversion from a dichotomous
to quantitative trait will result in minimal to potentially improved power to re-identify established
causal variants in GWAS. We plan to run future studies with larger cohort size to demonstrate that
quantitative proxy traits can improve performance by increasing the effective sample size.
4.5 Conclusions
Using EHR-derived model probabilities as quantitative traits to replace traditional case-control
assignment in genetic studies requires further analysis in larger cohorts, as demonstrated in our
under-powered venous thromboembolism genome-wide association study. The quantitative trait
proxy method did estimate observational stroke heritability, however, while traditional case-control
assignment failed. Our simulated study also suggests potential p-value improvement when convert-
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ing binary traits to quantitative, though future evaluation in a large cohort is needed.
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Chapter 5: QTPhenProxy, a supervised machine learning model that
leverages Electronic Health Record data to improve power in genome-wide
association studies in the UK Biobank
5.1 Introduction
Genome-wide association studies accumulate hundreds of thousands to millions of participants
to acquire adequate signal for variant discovery. High-throughput identification of cases and con-
trols can be difficult, however, due to time-consuming chart review and incompleteness of medi-
cal records. Current disease genome-wide association studies develop case-control sets in which
power relies on a large number of pure cases, and the missingness of EHR data could prevent
some cases from discovery in a high-throughput manner[13, 44, 136]. In addition, extreme case-
control imbalance in biobanks can lead to increased type 1 error when running linear mixed model
genome-wide association analysis[137]. An incorporation of additional accessible EHR data could
improve case curation sensitivity. In addition, many diseases such as stroke result from a combi-
nation of gene and environmental interactions, and there is significant overlap with comorbidities
in genome-wide significant variants[11]. Therefore, it is difficult to confirm every person without
the event is a control, suggesting the utility of a disease likelihood assignment[13, 138].
The definition of the disease phenotype influences the success of detecting a genetic signal
since power is generally calculated by number of cases and controls [17, 139]. We propose that in-
cluding EHR information about comorbidities[140] and other health information about the subject
in trait assignment can improve the power of GWAS. Past studies have shown that incorporating
diagnosis count improved the power of genetic studies, and the addition of patient questionnaires
and genetic correlations to hospital records improved detection of cases[141, 136, 142, 143]. In-
corporating EHR data to develop a probability of suicide attempt also improved the power of its
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genome-wide association study [143]. We argue that including several modalities of health data
to estimate assignment of case probability can improve the power of genomic studies. For ex-
ample, the most successful genome-wide association study for stroke required 40,585 cases and
406,111 controls[11]. We hypothesize that we can discover genome-wide significant variants as-
sociated with stroke with a fraction of those cases (4,354) by incorporating EHR information into
a quantitative trait assignment.
In this study, we use machine learning methods to expand sample cohorts by assigning every
patient a probability of disease. As described in Chapter 2, the probability represents patients along
a spectrum of the disease including those who have experienced stroke, those who are predisposed
to stroke but have not experienced a stroke, and those who have not had a stroke and do not have
stroke risk factors. We hypothesize that the output of a supervised machine learning classifier,
trained on the EHR data of a small number of known cases and controls, can be used as a proxy
variable for stroke and will be an efficient strategy for expanding cohort size. We demonstrate
that our quantitative proxy trait can improve power over its respective binary trait in ischemic
stroke. We also show that the new variants discovered are known in similar cardiovascular and
neurological diseases. We find up to 13 LD independent loci that pass genome-wide significance
and conditional analysis, and the majority of the associated genes are known to be associated
with stroke or cardiovascular disease. For stroke and its subtypes, ischemic stroke, subarachnoid
hemorrhage, and intracerebral hemorrhage, QTPhenProxy recovered known and discovered new
stroke variants with an order of magnitude fewer cases than traditional genome-wide association
studies.
5.2 Methods
5.2.1 QTPhenProxy Phenotyping Model.
We gathered clinical features of primary ICD10 diagnosis codes, OCPS4 procedure codes (UK
Biobank code 42100), medications (UK Biobank code 20003), race/ethnicity (UK Biobank code
1001), and age. 2018 served as the age end point. We mapped the OCPS4 procedure codes (UK
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Biobank code 240) to SNOMED-CT codes and the UK Biobank medication codes to RxNorm
codes by name[99, 144]. We also gathered data of self-reported and first occurrence of all stroke,
ischemic stroke, subarachnoid stroke, and intracerebral hemorrhage, asthma, COPD, myocardial
infarction, ST-elevation Myocardial infarction, and Non ST-elevation Myocardial Infarction. We
chose to study all 18 diseases that had a validated algorithmically defined outcome (category 42)
in the UK Biobank: the above stroke subtypes, myocardial infarction and two main subtypes:
STEMI and NSTEMI, asthma, COPD, dementia and three main subtypes: frontotemporal demen-
tia, vascular dementia, and Alzheimer’s disease, motor neuron disease (also known as ALS), and
Parkinson’s disease and three subtypes: Parkinsonism, Progressive Supranuclear Palsy, and Multi-
ple Systems Atrophy. We made a large matrix in which each extracted EHR feature was a binary
variable based on the presence or absence of the feature. We dichotomized age as greater than or
equal or less than 50 years. For each disease, we then defined the cases from the ICD10 code com-
binations described in the UK Biobank’s phenotyping algorithm[145]. We then trained 5 different
classifiers: 1) logistic regression with elastic net penalty, 2) logistic regression with L1 penalty, 3)
random forest, 4) Adaboost, and 5) gradient boosting classifiers on 50% of the cases and an equal
number of controls. Controls were identified as subjects without any ICD10 codes within the same
category as the Clinical Modification Clinical Classifications Software tool[102]. We then applied
the trained algorithm to the whole UK Biobank, resulting in a model probability or quantitative
trait proxy for each subject and each disease. For comparison, another phenotype file with binary
assignment of case and control for each disease was prepared as well. Table 5.4 shows the number
of cases available for each disease.
5.2.2 Evaluation of QTPhenProxy Model Performance.
To evaluate the performance of the QTPhenProxy model, we determined its ability to recover
cases when the defining ICD10 codes are removed. We trained 50% of the cases and an equal
number of controls on the clinical features described above using the EN and RF classifiers. We
chose these classifiers because of their overall high performance and because their probability
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assignment distributions were continuous (Figure 5.2). We removed the ICD10 codes used to
define the cases and controls in our feature set. We then tested the model on all other subjects
in the UK Biobank, which included known cases, and for some diseases such as Ischemic Stroke
and Myocardial Infarction, self-reported cases that did not have an ICD10 code for the disease.
We then evaluated the recovery of 1) cross-validation and 2) the holdout test set through Precision
at top 50, 100, 500, and number of cases, area under the receiver operating curve, area under the
precision recall curve, and maximum F1 score.
5.2.3 Genotyping and Imputation.
UK Biobank subjects that were of White British descent, were in the UK Biobank PCA calcu-
lations and therefore without 3rd degree and above relatedness, and were without aneuploidy were
used in this study, totalling 337147 subjects (181,032 females and 156,115 males)[146, 28]. Of the
nearly 500,000 participants, approximately 50,000 subjects were genotyped on the UK BiLEVE
Array by Affymetrix while the rest were genotyped using the Applied Biosystems UK Biobank
Axiom Array with over 800,000 markers. The arrays share 95% marker coverage. Initially, we ran
a QC extracting markers with an MAF>0.5%, INFO score > 0.3, and Hardy-Weinberg equilib-
rium test mid-p-value > 10−10 using all subjects, which we will refer to as QC1. QC1 was run for
GWAS of all 18 diseases. We then re-ran the QC, which we will refer to as QC2, more stringently
by extracting markers with an MAF>1%, INFO score > 0.8, and Hardy-Weinberg equilibrium
test mid-p-value > 10−5 using Plink2[147]. UKBB version 3 Imputation combined the Haplotype
Research Consortium with the UK10K haplotype resource using the software IMPUTE4[146].
5.2.4 Genome-wide Association Analysis.
The binary trait and QTPhenProxy probabilities were compared by running two separate as-
sociation analyses. For both analyses, covariates included age at 2018, sex, first 10 principal
components, and the genotyping array the sample was carried out on. In QC1, the original PCs
determined by the UK Biobank QC were used. In QC2, we calculated the PCs using the method
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described in Method 5.2.11. QC2 GWAS was only run for stroke, ischemic stroke, subarachnoid
hemorrhage, and intracerebral hemorrhage GWAS. For the binary trait GWAS, a logistic regres-
sion was run, adjusted with the aforementioned covariates. For comparison, the QTPhenProxy
probabilities were quantile normalized and run under a linear regression adjusting for the same co-
variates. We also permuted the probabilities within the phenotyping files and ran additional GWAS
10 times to ensure the signal was correlated with the phenotype.
5.2.5 Mapping variants to known disease variant marker sets and mapping marker sets to disease
systems.
The EBI-GWAS catalogue has a database of all published GWAS[128]. We extracted over
2,000 disease marker sets conducted on populations with European ancestry. MedDRA is a stan-
dardized medical vocabulary developed by the International Council for Harmonisation of Techni-
cal Requirements for Pharmaceuticals for Human Use (ICH)[148]. All terms in the vocabulary can
be mapped to its highest system level, which includes 27 different organ systems and other general
and lab studies such as social circumstance and investigations. Using the NCBO annotator, we
mapped the names of the EBI-GWAS disease marker sets to the MedDRA System Organ Classes
level[149].
5.2.6 Assessing the specificity of the QTPhenProxy-derived variants.
To assess the disease specificity of the genome-wide significant variants, we first calculated the
proportion of genome-wide significant variants in each of the EBI-GWAS disease marker sets. We
then aggregated the marker sets together by System Organ Class to evaluate the systems enriched
for genome-wide significant variants. We ordered the marker sets in each class by proportion of
genome-wide significant variants and divided by the number of marker sets in each class. We
also compared the proportion of variants of varying significance of the marker sets related to each
disease with 1) the other marker sets related to the same System Organ Class as the disease and
2) all other marker sets. We stratified each comparison by significance value, between 0.05 and
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5E-08.
5.2.7 Evaluation of recovery of known variants
For each disease, we gathered EBI-GWAS marker sets that contained the disease in its name.
These represent known variants of each disease. We then extracted the p-value from either the
binary trait logistic regression or QTPhenProxy linear regression. We then ran a t-test comparing
the negative log base 10 p-values of the binary trait with QTPhenProxy GWAS. We also ran a
t-test comparing the difference between the binary and QTPhenProxy log base 10 p-values for the
known ischemic stroke variants and an equivalent number of random variants.
5.2.8 Refinement of discovered variants by QTPhenProxy using conditional analysis
At each LD-independent locus, the SNP with lowest p-value may not be the variant that causes
the most phenotypic variation within the area[150]. Therefore, we applied GCTA-COJO, a condi-
tional analysis that takes into account lead SNPs and the LD structure of a sample of the population,
to our genome-wide association results[150]. We randomly sampled 10,000 subjects from the UK-
Biobank for the linkage disequilibrium calculation[151]. From the GCTA-COJO results, we then
mapped each locus to its nearest gene using dbSNP and the UCSC Genome Browser accessed at
http://genome.ucsc.edu/[152, 153]. For intergenic loci, we chose the 1-2 nearest genes that were
at most 10,000 kbps away.
5.2.9 Correlation of QTPhenProxy GWAS beta coefficients to Binary trait GWAS Odds Ratio
We calculated the Pearson correlation between the beta-coefficients of the QTPhenProxy GWAS
and log of the odds ratios of the Binary trait GWAS. In order to account for noise, we calculated the
correlation with variants with different levels of significance in the QTPhenProxy models. P-value
cutoffs included 1, 0.05,0.0005,5e-06,and 5e-08.
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5.2.10 Simulation of Conversion of QTPhenProxy trait to Binary trait and Conversion of beta
coefficients to odds ratios
In order to validate our method of converting binary traits to quantitative traits, we ran simula-
tions and tested the correlation between the two methods. Using SOLAR, a software package for
estimating heritability using identity by descent calculations, we simulated a quantitative trait with
one quantitative trait locus with two alleles and a nearby marker locus with two alleles[124]. We
first removed all related individuals with a resulting cohort of 4,195 subjects. For the simulation,
we varied the frequency for the causal minor allele and a marker minor allele from 0.05-0.45 in
increments of 0.010, the mean quantitative trait value for the heterozygous genotype from 5-45 in
increments of 10 and the homozygous genotypes’ mean±50, the standard deviation of the quantita-
tive trait from 5-20 in increments of 4, and the recombinant fraction from 0.01-0.10 in increments
of 0.02. After simulating the quantitative trait distribution, we then normalized the trait to several
distributions: standard normal, normal distribution with mean 0 and standard deviation 10, and
mean 50 and standard deviation 10. We compared distributions because we quantile normalized
our QTPhenProxy trait values before running the genome-wide associations studies. We then con-
verted each simulation to a binary trait using liability thresholding[154]. Liability thresholding
was implemented as follows: We determined a quantitative trait value as a threshold based off the
prevalence of the simulated trait, which we varied from 2.5-20% in increments of 5%. Any sub-
ject above this threshold is labeled a case and the rest, controls, in the binary trait phenotype. We
then ran linear or logistic regressions using the python package statsmodels between the simulated
quantitative trait or the binary trait and the subjects’ genotypes for the marker and causal loci[155].
We developed a conversion formula for the beta coefficients to odds ratios by linearly regressing
the correlation between the simulated effect sizes. We then converted the beta-coefficients to odds
ratios of the UK Biobank GWAS results by multiplying the beta coefficient by the average slope
and intercept and then taking the exponential of the result.
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5.2.11 PCA
In order to confirm the cases were well distributed within the data and to determine the number
of principal components to use as covariates, we conducted PCA. For each of the four diseases,
we first pruned the variants used for PCA by running a sliding window of size 100 kbps, 5 variant
step size, and r2 threshold of 0.1. We then combined the chromosomes, extracting only the pruned
variants, using Plink2 and cat-bgen software[156]. We then ran PCA with Plink2[147] and eval-
uated the PCs to be used as covariates using a skree plot. Within the main PCs, we plotted them
against each other, highlighting the distribution of the cases.
5.2.12 LD Score Regression and evaluation of genomic inflation
We determined the lambda genomic correction and LD score regression coefficient using the
software LDSC[157]. We used the disease GWAS summary statistics and European LD scores pre-
computed from 1000 genomes by the Alkes group[157]. QQ plots were plotted using qqman[158].
To determine the relationship between genomic inflation and minor allele frequency, we binned
all variants in the stroke GWAS by minor allele frequency into 30 bins. We then calculated the
genomic inflation of the p-values of the variants in each bin.
5.2.13 Genetic Correlation of QTPhenProxy with MEGASTROKE and Coronary Artery Disease
GWAS
We measured the genetic correlation of the QTPhenProxy EN stroke model with QC1 quality
control with the MEGASTROKE all stroke GWAS summary statistics[11] and coronary artery




5.3.1 QTPhenProxy Model Performance
We trained models with 5 different classifier types and the 18 disease phenotypes as defined by
the UK Biobank Algorithmically Defined Outcomes rubric[145]. Random forest models overall
showed the best area under the receiver operating curve and Adaboost models gave the best area
under the precision recall curve on the hold-out test set. Overall stroke, followed by ischemic
stroke, showed high precision at top 50 patients ordered by probability (Figure 5.1, tables 5.1,
5.2 and 5.5). We chose the probabilities from the EN and RF models to run the genome-wide
association analyses because the distribution of their probabilities was continuous and included
values from 0-1 (Figure 5.2).
Disease Model AUROC AUPRC Maximum F1
Ischemic Stroke
rf 0.953(0.000279) 0.248(0.00201) 0.326(0.00229)
ab 0.950(0.000504) 0.246(0.00465) 0.316(0.00335)
lr 0.946(0.000409) 0.239(0.0021) 0.322(0.00196)
gb 0.952(0.000686) 0.210(0.00479) 0.294(0.00319)
en 0.943(0.000362) 0.209(0.00193) 0.295(0.00199)
SAH Stroke
rf 0.875(0.000746) 0.144(0.00299) 0.242(0.00423)
ab 0.859(0.00186) 0.171(0.0062) 0.271(0.00807)
lr 0.850(0.00115) 0.151(0.00419) 0.291(0.00509)
gb 0.863(0.00149) 0.113(0.00379) 0.203(0.00513)
en 0.863(0.000958) 0.109(0.00377) 0.198(0.00497)
ICH Stroke
rf 0.903(0.000924) 0.0483(0.00143) 0.116(0.00253)
ab 0.900(0.00171) 0.0480(0.00196) 0.114(0.00305)
lr 0.879(0.00145) 0.0270(0.000709) 0.0762(0.00137)
gb 0.900(0.00123) 0.0365(0.00125) 0.0935(0.00227)
en 0.903(0.00118) 0.0329(0.000755) 0.0861(0.00146)
Stroke
rf 0.899(0.000404) 0.326(0.0016) 0.375(0.00147)
ab 0.906(0.000711) 0.335(0.00423) 0.380(0.00262)
lr 0.905(0.000528) 0.314(0.00143) 0.368(0.00154)
gb 0.903(0.00047) 0.292(0.00245) 0.355(0.00151)
en 0.896(0.000448) 0.282(0.00113) 0.350(0.000962)
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Disease Model AUROC AUPRC Maximum F1
NSTEMI
rf 0.943(0.000192) 0.168(0.000887) 0.263(0.0012)
ab 0.94(0.000469) 0.195(0.00169) 0.286(0.00153)
lr 0.941(0.000234) 0.189(0.00102) 0.281(0.00112)
gb 0.937(0.00617) 0.173(0.0111) 0.262(0.0127)
en 0.94(0.000244) 0.173(0.000975) 0.258(0.00099)
Disease Model AUROC AUPRC Maximum F1
STEMI
rf 0.977(0.000154) 0.193(0.00203) 0.275(0.00208)
ab 0.978(0.000287) 0.223(0.00227) 0.308(0.00206)
lr 0.977(0.000262) 0.211(0.00169) 0.296(0.00149)
gb 0.973(0.00694) 0.204(0.012) 0.283(0.0145)
en 0.974(0.000216) 0.181(0.00142) 0.26(0.00159)
Disease Model AUROC AUPRC Maximum F1
MI
rf 0.935(0.000197) 0.356(0.001) 0.424(0.000676)
ab 0.941(0.000156) 0.384(0.00123) 0.465(0.00106)
lr 0.941(0.000153) 0.367(0.000968) 0.44(0.00087)
gb 0.94(0.000161) 0.365(0.00105) 0.434(0.000826)
en 0.931(0.000181) 0.335(0.000798) 0.392(0.000694)
Disease Model AUROC AUPRC Maximum F1
MSA
rf 0.952(0.00188) 0.00639(0.00107) 0.0317(0.00395)
ab 0.945(0.00324) 0.00393(0.000431) 0.0203(0.00272)
lr 0.822(0.00886) 0.00125(3.59e-05) 0.00347(5.82e-05)
gb 0.951(0.00224) 0.00439(0.00057) 0.022(0.00231)
en 0.952(0.00189) 0.00353(0.000161) 0.0176(0.0015)
Disease Model AUROC AUPRC Maximum F1
Motor Neuron
rf 0.927(0.00256) 0.0349(0.00328) 0.111(0.00752)
ab 0.91(0.00428) 0.0162(0.00137) 0.0684(0.00503)
lr 0.795(0.00795) 0.0217(0.00318) 0.1(0.00826)
gb 0.917(0.00333) 0.0165(0.00167) 0.0646(0.00521)
en 0.909(0.00398) 0.0151(0.00144) 0.0629(0.00491)
Disease Model AUROC AUPRC Maximum F1
Parkinson’s
rf 0.886(0.0013) 0.063(0.00302) 0.139(0.00371)
ab 0.863(0.00172) 0.0667(0.00477) 0.153(0.00694)
lr 0.842(0.00188) 0.0549(0.00323) 0.14(0.00562)
gb 0.866(0.00144) 0.0234(0.00113) 0.0705(0.00242)
en 0.87(0.00164) 0.0264(0.00104) 0.0819(0.00241)
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Disease Model AUROC AUPRC Maximum F1
Parkinsonism
rf 0.908(0.000947) 0.0659(0.00119) 0.138(0.00175)
ab 0.901(0.00141) 0.0606(0.00258) 0.124(0.00382)
lr 0.898(0.00119) 0.0583(0.000865) 0.121(0.00117)
gb 0.903(0.00101) 0.0515(0.000953) 0.112(0.00182)
en 0.897(0.00114) 0.0494(0.00069) 0.112(0.00121)
Disease Model AUROC AUPRC Maximum F1
COPD
rf 0.915(0.000342) 0.2(0.00144) 0.266(0.00137)
ab 0.915(0.000431) 0.224(0.00306) 0.292(0.00182)
lr 0.915(0.000339) 0.245(0.00116) 0.303(0.00107)
gb 0.915(0.000321) 0.215(0.00146) 0.283(0.00133)
en 0.906(0.000415) 0.197(0.000952) 0.264(0.00111)
Disease Model AUROC AUPRC Maximum F1
Asthma
rf 0.806(0.000366) 0.165(0.000643) 0.23(0.000714)
ab 0.804(0.000447) 0.185(0.00118) 0.254(0.000653)
lr 0.808(0.000415) 0.197(0.000627) 0.254(0.000564)
gb 0.807(0.000323) 0.176(0.000695) 0.238(0.000683)
en 0.79(0.000501) 0.146(0.000474) 0.211(0.000552)
Disease Model AUROC AUPRC Maximum F1
Vascular Dementia
rf 0.93(0.00228) 0.0158(0.00127) 0.0652(0.00345)
ab 0.906(0.00334) 0.0105(0.00101) 0.0516(0.00376)
lr 0.887(0.00374) 0.00842(0.000719) 0.0486(0.00442)
gb 0.922(0.00245) 0.0116(0.00082) 0.0539(0.00368)
en 0.919(0.00294) 0.0137(0.000906) 0.0615(0.00337)
Disease Model AUROC AUPRC Maximum F1
Alzheimer’s
rf 0.877(0.00215) 0.00989(0.000578) 0.0468(0.00245)
ab 0.846(0.00367) 0.00697(0.000334) 0.0371(0.00215)
lr 0.808(0.00269) 0.00453(0.000162) 0.0305(0.00116)
gb 0.857(0.00321) 0.00675(0.000255) 0.0359(0.00199)
en 0.857(0.00285) 0.00646(0.000277) 0.0348(0.00205)
Disease Model AUROC AUPRC Maximum F1
All Dementia
rf 0.895(0.00101) 0.0536(0.00112) 0.115(0.00181)
ab 0.905(0.00106) 0.09(0.0042) 0.192(0.00907)
lr 0.887(0.0011) 0.119(0.00235) 0.243(0.00355)
gb 0.905(0.000731) 0.0567(0.000921) 0.116(0.00162)
en 0.878(0.0014) 0.0441(0.000976) 0.105(0.00182)
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Table 5.1: Phenotyping Models Performance. rf : Random Forest, ab= Adaboost, lr=Logistic
regression with L1 penalty, gb=Gradient Boosting, en=Logistic Regression with elastic net penalty
models. AUROC: Area under the Receiver Operating Curve, AUPRC: Area under Precision-Recall
curve. 95% confidence intervals
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
IscStroke
rf 0.739(0.0132) 0.682(0.0105) 0.544(0.00575) 0.322(0.00246)
ab 0.71(0.0192) 0.674(0.0154) 0.527(0.0117) 0.309(0.00405)
lr 0.801(0.0143) 0.672(0.00997) 0.483(0.00560) 0.314(0.00205)
gb 0.609(0.0305) 0.544(0.0246) 0.425(0.0179) 0.282(0.00714)
en 0.74(0.0141) 0.63(0.00946) 0.435(0.00476) 0.29(0.00197)
SAHStroke
rf 0.607(0.0178) 0.55(0.0106) 0.308(0.00623) 0.235(0.00381)
ab 0.627(0.0185) 0.538(0.0144) 0.329(0.0102) 0.266(0.00801)
lr 0.535(0.0187) 0.5(0.0147) 0.356(0.00722) 0.271(0.00630)
gb 0.532(0.0203) 0.442(0.0176) 0.249(0.00759) 0.197(0.00557)
en 0.543(0.0188) 0.441(0.0136) 0.244(0.00773) 0.192(0.00523)
ICHStroke
rf 0.263(0.013) 0.216(0.00968) 0.124(0.00328) 0.110(0.00265)
ab 0.203(0.0185) 0.171(0.0124) 0.108(0.00400) 0.0997(0.00352)
lr 0.109(0.0121) 0.100(0.00713) 0.0742(0.00252) 0.0677(0.0027)
gb 0.137(0.0146) 0.123(0.00838) 0.0908(0.00279) 0.0834(0.00240)
en 0.123(0.0110) 0.115(0.00761) 0.0835(0.00262) 0.0768(0.00204)
Stroke
rf 0.974(0.00548) 0.941(0.00506) 0.822(0.00339) 0.374(0.0015)
ab 0.940(0.0120) 0.910(0.0120) 0.813(0.0131) 0.378(0.00265)
lr 0.929(0.00793) 0.872(0.00678) 0.775(0.00413) 0.365(0.00164)
gb 0.868(0.0324) 0.818(0.0309) 0.696(0.0180) 0.351(0.00166)
en 0.848(0.00829) 0.836(0.00706) 0.694(0.00394) 0.345(0.000996)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
NSTEMI
rf 0.367(0.0151) 0.35(0.0117) 0.293(0.00471) 0.228(0.00161)
ab 0.454(0.0224) 0.428(0.016) 0.361(0.00636) 0.258(0.00208)
lr 0.498(0.0128) 0.452(0.00926) 0.346(0.00383) 0.251(0.00117)
gb 0.4(0.0451) 0.363(0.0379) 0.296(0.028) 0.224(0.0189)
en 0.494(0.0136) 0.438(0.00987) 0.329(0.00347) 0.23(0.00129)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
STEMI
rf 0.376(0.019) 0.38(0.0137) 0.336(0.00505) 0.248(0.00252)
ab 0.446(0.0192) 0.429(0.0146) 0.365(0.00649) 0.27(0.0026)
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lr 0.45(0.0116) 0.459(0.0087) 0.355(0.00515) 0.253(0.00195)
gb 0.399(0.0326) 0.388(0.03) 0.341(0.0248) 0.245(0.0174)
en 0.365(0.0117) 0.363(0.00947) 0.328(0.00404) 0.233(0.0015)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
MI
rf 0.706(0.0139) 0.677(0.0103) 0.623(0.00441) 0.414(0.000878)
ab 0.773(0.0107) 0.755(0.00615) 0.668(0.00409) 0.449(0.00128)
lr 0.772(0.00873) 0.749(0.00669) 0.685(0.00369) 0.419(0.000945)
gb 0.746(0.0159) 0.751(0.0125) 0.684(0.00506) 0.414(0.000937)
en 0.884(0.00827) 0.82(0.0062) 0.706(0.00302) 0.381(0.000827)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
MSA
rf 0.0256(0.00608) 0.0164(0.00332) 0.0102(0.00112) 0.0185(0.00401)
ab 0.008(0.00314) 0.007(0.00237) 0.00756(0.00114) 0.00765(0.00264)
lr 0.0036(0.00213) 0.0018(0.00106) 0.00036(0.000213) 0.00222(0.00131)
gb 0.0128(0.0038) 0.01(0.00235) 0.0066(0.000916) 0.0109(0.00271)
en 0.0032(0.00203) 0.0058(0.00176) 0.0058(0.000817) 0.00469(0.0018)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
Motor Neuron
rf 0.164(0.0154) 0.112(0.0089) 0.041(0.00221) 0.0965(0.00728)
ab 0.058(0.00832) 0.0526(0.00636) 0.0346(0.00249) 0.0491(0.0057)
lr 0.0968(0.0181) 0.0632(0.00948) 0.0449(0.00521) 0.0567(0.00727)
gb 0.07(0.00949) 0.0552(0.00618) 0.0311(0.00227) 0.0518(0.00502)
en 0.0568(0.00779) 0.0492(0.00531) 0.031(0.0024) 0.0469(0.00505)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
Parkinson’s
rf 0.394(0.0231) 0.309(0.0142) 0.157(0.00497) 0.133(0.00369)
ab 0.33(0.0263) 0.274(0.02) 0.167(0.00887) 0.147(0.00706)
lr 0.331(0.0215) 0.26(0.0149) 0.154(0.00693) 0.135(0.00578)
gb 0.12(0.0107) 0.102(0.00862) 0.0668(0.00329) 0.0617(0.00258)
en 0.129(0.012) 0.117(0.00671) 0.0793(0.00327) 0.0725(0.00277)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
Parkinsonism
rf 0.279(0.0177) 0.261(0.0115) 0.191(0.00419) 0.131(0.00218)
ab 0.316(0.0202) 0.276(0.015) 0.18(0.00716) 0.117(0.00368)
lr 0.214(0.0116) 0.198(0.00881) 0.156(0.00365) 0.112(0.00144)
gb 0.208(0.0134) 0.185(0.0105) 0.129(0.00372) 0.0977(0.00187)
en 0.188(0.0115) 0.19(0.00905) 0.122(0.00319) 0.102(0.00144)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
COPD
rf 0.784(0.017) 0.732(0.0123) 0.567(0.00564) 0.261(0.00162)
ab 0.776(0.0194) 0.738(0.0188) 0.607(0.0139) 0.288(0.00201)
lr 0.878(0.00797) 0.831(0.00528) 0.681(0.00474) 0.301(0.00116)
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gb 0.766(0.0138) 0.719(0.0114) 0.584(0.0062) 0.279(0.00134)
en 0.762(0.00879) 0.742(0.00626) 0.575(0.00457) 0.261(0.00109)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
Asthma
rf 0.538(0.0183) 0.542(0.0125) 0.517(0.00457) 0.225(0.000823)
ab 0.743(0.0162) 0.708(0.0103) 0.582(0.00752) 0.251(0.000822)
lr 0.831(0.00915) 0.808(0.00623) 0.677(0.00463) 0.251(0.000607)
gb 0.761(0.0167) 0.725(0.0118) 0.599(0.00578) 0.233(0.000811)
en 0.703(0.00917) 0.627(0.00856) 0.502(0.00402) 0.201(0.000615)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
Vascular Dementia
rf 0.0612(0.0081) 0.0532(0.00556) 0.033(0.00176) 0.0493(0.00461)
ab 0.0432(0.00802) 0.041(0.00579) 0.0255(0.00175) 0.0382(0.00473)
lr 0.034(0.0108) 0.0268(0.00702) 0.0187(0.00317) 0.0226(0.0059)
gb 0.052(0.00844) 0.0434(0.00507) 0.0268(0.00168) 0.0394(0.00417)
en 0.056(0.00815) 0.0528(0.00557) 0.0304(0.00162) 0.0488(0.00417)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
Alzheimer’s
rf 0.0556(0.00847) 0.0506(0.00462) 0.0311(0.00189) 0.0386(0.0029)
ab 0.0388(0.00631) 0.0332(0.00448) 0.0231(0.0017) 0.028(0.00259)
lr 0.0156(0.00499) 0.0134(0.00374) 0.0139(0.00213) 0.0121(0.00255)
gb 0.03(0.00568) 0.0302(0.00409) 0.0223(0.00156) 0.0277(0.00219)
en 0.0236(0.00681) 0.0268(0.00465) 0.0214(0.00182) 0.0239(0.00234)
Disease Model Prec at 50 Prec at 100 Prec at 500 Prec at N
All Dementia
rf 0.323(0.0125) 0.281(0.00994) 0.177(0.00397) 0.112(0.00193)
ab 0.247(0.0144) 0.235(0.0127) 0.198(0.00998) 0.168(0.00964)
lr 0.38(0.0138) 0.351(0.00989) 0.26(0.00573) 0.211(0.00496)
gb 0.178(0.0134) 0.178(0.00971) 0.146(0.0035) 0.106(0.00173)
en 0.132(0.0121) 0.14(0.00831) 0.138(0.00381) 0.0975(0.00189)
Table 5.2: Precision at top 50, 100, 500, and N cases probabilities of phenotyping models.
rf : Random Forest, ab= Adaboost, lr=Logistic regression with L1 penalty, gb=Gradient Boosting,
en=Logistic Regression with elastic net penalty models. Prec: Precision. 95% confidence intervals
















































































































Table 5.3: Sensitivity and Specificity of phenotyping models. rf : Random Forest, ab= Adaboost,
lr=Logistic regression with L1 penalty, gb=Gradient Boosting, en=Logistic Regression with elastic
net penalty models. 95% confidence intervals
5.3.2 Variants recovered by QTPhenProxy for all stroke, ischemic stroke, subarachnoid hemor-
rhage, intracerebral hemorrhage, and improvement over traditional binary method using the
QC1 markers and principal components
The binary trait logistic regression genome-wide association study for stroke, ischemic stroke,
and subarachnoid hemorrhage recovered no variants with genome-wide significance. Binary trait
logistic regression genome-wide association study for intracerebral hemorrhage recovered 2 vari-
ants with genome-wide significance. Quantitative trait linear regression using QTPhenProxy prob-
abilities for stroke recovered 120 genome-wide significant SNPs with 16 LD-independent loci and
1215 genome-wide significant SNPs with 39 LD-independent loci, for ischemic stroke recovered
202 genome-wide significant SNPs with 15 LD-independent loci, and 1266 genome-wide signifi-
cant SNPs with 46 LD-independent loci, for subarachnoid hemorrhage recovered 69 genome-wide
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Figure 5.1: Precision at top 50, 100, 500, and N cases probabilities assigned by machine learn-
ing algorithms on hold out test set. A. All Stroke, B. Ischemic Stroke, C. Subarachnoid Hemor-
rhage, D. Intracerebral Hemorrhage. Circles represent precision for the Logistic Regression model
with L1 penalty, squares: Random Forest model, triangles: Adaboost model, cross: Gradient
boosting model, and star Logistic Regression model with Elastic Net penalty.
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Figure 5.2: Model probability distributions assigned by machine learning algorithms. RF:
Random Forest model, EN: Logistic Regression with elastic net penalty model, LR: Logistic Re-
gression model with L1 penalty, AB: Adaboost model,GB: Gradient boosting model, IscStroke:
Ischemic Stroke phenotype,SAHStroke: Subarachnoid hemorrhage phenotype,ICHStroke: Intrac-
erebral hemorrhage phenotype
significant SNPs with 4 LD-independent loci, and 722 genome-wide significant SNPs with 40 LD-
independent loci, and for intracerebral hemorrhage recovered 146 genome-wide significant SNPs
with 8 LD-independent loci, and 1059 genome-wide significant SNPs with 54 LD-independent
loci using the EN and RF classifiers, respectively (Table 5.4). We show the comparison of genome-
wide significant variants between the QTPhenProxy EN model and Binary trait GWAS for stroke
in a Hudson plot (Figure 5.3)[160]. Out of known ischemic stroke variants, both models also re-
covered 3 known variants with genome-wide significance, and the EN model recovered 21/49 of
the known variants, equivalent to a sensitivity of 0.428, while the traditional binary trait recov-
ered 15/49, (sensitivity=0.306), and RF model recovered 14/49 (sensitivity=0.286) with nominal
p-value of 0.05 (Table 5.5). For all stroke, sensitivity of known stroke variants was 0.333 using the
EN model, 0.261 using the RF model, and 0.202 using the binary trait. Subarachnoid hemorrhage
did not have a specific EBI-GWAS disease marker set, and the EBI-GWAS disease marker set for
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Figure 5.3: QQ Plots and Hudson plot of QTPhenProxy genome-wide association analysis,
EN Model with Binary trait genome-wide association analysis for Stroke, using QC1 quality
control. A. Q-Q Plot for QTPhenProxy, EN Model GWAS. B. Q-Q Plot for Binary trait GWAS.
C. Top Manhattan plot is for QTPhenProxy, bottom plot for binary trait. Variants with p-value <
5e-08 are highlighted in pink, and the dashed lines are at the same value.
binary method and QTPhenProxy method for known ischemic stroke variants was significantly
increased compared to the same number of random variants using the EN classifier (two sample
t test, t=2.43, p=0.0184 for EN classifier and t=1.74, p=0.0876 for RF classifier). In addition,
QTPhenProxy with EN classifier showed a significant decrease in p-value of all known ischemic
stroke variants compared to traditional binary method (two sample t-test, t=-2.1 p=0.0367) while
QTPhenProxy with RF classifier did not show a significant decrease (t=-1.48,p=0.144). The dif-
ference in p-values between the binary method and QTPhenProxy method for known all stroke
variants was significantly increased compared to the same number of random variants for the EN
classifier (t=2.80, p=0.00638) but not significant for the RF classifier (t=0.737,p=0.463). In addi-
tion, QTPhenProxy with EN classifier showed a decrease in p-value of all known stroke variants
compared to traditional binary method (two sample t-test, t=-1.87 p=0.0639) while QTPhenProxy
with RF classifier did not show a significant decrease (t=-1.05,p=0.298).
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Disease N Cases Bin Hits RF Hits RF AUROC EN Hits EN AUROC
Asthma 21491 8548 3946 0.805 3117 0.79
COPD 8290 82 2544 0.915 2088 0.906
All cause Dementia 2279 36 550 0.85 91 0.878
Alzheimer’s disease 357 72 1356 0.876 196 0.856
Vascular dementia 178 34 1832 0.93 611 0.919
Frontotemporal Dementia 39 6 1655 NA 0 NA
Motor neuron disease 173 1 1652 0.927 48 0.908
Myocardial Infarction 9407 487 2126 0.935 940 0.931
STEMI 3386 82 1806 0.977 563 0.974
NSTEMI 3932 137 2922 0.943 459 0.94
Parkinsonism 2321 3 881 0.908 41 0.897
Parkinson’s disease 934 3 997 0.885 3 0.87
Progressive supranuclear palsy 14 34 3789 NA 40 NA
Multiple System Atrophy 120 14 1386 0.952 15 0.952
Stroke 4354 0 1215 0.899 120 0.896
Ischemic stroke 3308 0 1266 0.952 202 0.943
Intracerebral hemorrhage 581 2 1059 0.903 146 0.903
Subarachnoid hemorrhage 665 0 722 0.875 69 0.862
Table 5.4: Number of genome-wide significant variants. N Cases: number of cases. hits: Num-
ber of genome-wide significant variants, Bin: binary trait, RF: Random Forest model, EN: Logistic
Regression with elastic net penalty model.
Disease Bin Sens RF Sens EN Sens
Asthma 0.667 0.458 0.513
COPD 0.254 0.182 0.2
All cause Dementia 0 1 1
Alzheimer’s disease 0.285 0.155 0.173
Myocardial Infarction 0.789 0.71 0.736
Parkinsonism 0.473 0.231 0.0842
Stroke 0.217 0.217 0.261
Ischemic stroke 0.312 0.312 0.333
Table 5.5: Proportion of known stroke variants that reach nominal significance for each
model. N Cases: number of cases, sens: sensitivity measure for each model GWAS and binary
trait GWAS, measures what proportion of known stroke variants reach genome-wide significance
in each association test. Bin: binary trait, RF: Random Forest model, EN: Logistic Regression
with elastic net penalty model.
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5.3.3 Variants recovered by QTPhenProxy for all stroke, ischemic stroke, subarachnoid hemor-
rhage, intracerebral hemorrhage, and improvement over traditional binary method using the
QC2 markers and principal components
The binary trait logistic regression genome-wide association study for stroke, ischemic stroke,
and subarachnoid hemorrhage recovered no variants with genome-wide significance. Binary trait
logistic regression genome-wide association study for intracerebral hemorrhage recovered 2 vari-
ants with genome-wide significance. Quantitative trait linear regression using QTPhenProxy prob-
abilities for stroke recovered 7 LD-independent loci, 3 LD-independent loci, for ischemic stroke,
3 LD-independent loci for subarachnoid hemorrhage, and 3 LD-independent loci for intracerebral
hemorrhage using the EN classifier. We show the comparison of genome-wide significant variants
between the EN and Binary in a Hudson plot (Figure 5.4)[160]. Out of known ischemic stroke
variants, both models also recovered 3 known variants with genome-wide significance, and the
EN model recovered 16/49 of the known variants, equivalent to a sensitivity of 0.326, while the
traditional binary trait recovered 15/49, (sensitivity=0.306), and RF model recovered 15/49 (sensi-
tivity=0.306) with nominal p-value of 0.05 (Figure 5.5). For all stroke, sensitivity of known stroke
variants was 0.265 using the EN model, 0.220 using the RF model, and 0.220 using the binary
trait. The t-tests referred to in Result 5.3.2 did not show significance.
5.3.4 Conditional analysis refines candidate variants to mostly lead some nearby SNPs.
Conditional analysis of the GWAS with QC1 quality control for the QTPhenProxy EN model
for all stroke identified 13 candidate variants with genome-wide significance, all of which are
novel, though some of the nearest genes to these loci have been identified in previous studies
through nearby loci. There were 12 loci identified for the stroke subtype ischemic stroke, 3 loci
for subarachnoid hemorrhage, and 9 loci for intracerebral hemorrhage (Table 5.6). Several loci
overlapped across stroke and some subtypes. Position 46705193 on chromosome 11, which is
in an intronic section of ARHGAP1[152], showed genome-wide significance in stroke, ischemic
stroke, and intracerebral hemorrhage. A missense mutation at locus rs6025 in the F5 gene showed
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Figure 5.4: QQ Plots and Hudson plot of QTPhenProxy genome-wide association analysis,
EN Model with Binary trait genome-wide association analysis for Stroke, using QC2 quality
control. QQ Plots and Hudson plot of QTPhenProxy genome-wide association analysis, EN Model
with Binary trait genome-wide association analysis for Stroke, using QC2 quality control. QQ
Plots and Hudson plot of QTPhenProxy genome-wide association analysis, EN Model with Binary
trait genome-wide association analysis for Stroke, using QC2 quality control. A. Q-Q Plot for
QTPhenProxy, EN Model GWAS. B. Q-Q Plot for Binary trait GWAS. C. Top Manhattan plot is
for QTPhenProxy, bottom plot for binary trait. Variants with p-value < 5e-08 are highlighted in




















































































































































































































































UKB Algo. Isc. Stroke, Binary
UKB Algo. Isc. Stroke, RF QT
UKB Algo. Isc. Stroke, EN QT
Figure 5.5: QTPhenProxy recovers known ischemic stroke variants. Results from QTPhen-
Proxy GWAS with QC2 quality control. Horizontal axis shows Ischemic Stroke variants cata-
logued in EBI-GWAS that have shown genome-wide significance in previous studies. Black mark-
ers represent p-values of variants recovered by QTPhenProxy models (square=RF,Triangle=EN).
98
genome-wide significance across stroke, intracerebral hemorrhage, and locus rs1894692, which is
near the F5 gene[152], showed genome wide significance in ischemic stroke. Additional loci that
showed genome-wide significance in both all stroke and ischemic stroke included those that are
intronic to LPA and NOS3 and nearby to APOC1P1/APOC1 and CDKN2A/CDKN2B[152]. Finally,
all stroke and intracerebral hemorrhage shared additional loci that showed genome-wide signifi-
cance after conditional analysis, which were nearby LOC105377992 and RPS4X9[152]. All stroke
genome-wide significant variants also included intronic loci in the MTA3, SOX7, ABO, FURIN, and
PLCB1 genes[152]. Ischemic stroke genome-wide significant variants included intronic loci in the
LPAL2 gene, intergenic loci in the PITX2, LDLR, and an insertion mutation in the ABO gene[152].
Subarachnoid hemorrhage genome-wide significant variants included an intronic locus in the ABO
gene. Finally, intracerebral hemorrhage genome-wide significant variants included a missense mu-
tation loci in the ABCG8 gene, and intronic loci in the NOS3 and XKR6 genes[152]. The variants
near or in LOC105377992, NOS3, CDKN2A/CDKN2B, LPA, LDLR, ABCG8, and RPS4X9 were
below nominal significance of 0.05 in the MEGASTROKE stroke and ischemic stroke GWAS of
European ancestry (Table 5.7)[11].
Phenotype rsID Chr. Gene Location Allele RAF Beta Converted OR P value
Stroke rs6025 1q24.2 F5 missense T/C 0.0231 0.0492 (0.0421-0.0564) 1.09 (1.08-1.10) 4.87e-12
Stroke rs8179838 2p21 MTA3 intronic T/C 0.621 0.0126 (0.0104-0.0149) 1.02 (1.02-1.03) 9.63e-09
Stroke rs6923947 6q22.32 LOC105377992 intergenic A/G 0.447 0.0123 (0.0101-0.0144) 1.02 (1.02-1.02) 1.19e-08
Stroke rs55730499 6q25.3 LPA intronic T/C 0.0817 0.0273 (0.0234-0.0312) 1.05 (1.04-1.06) 2.70e-12
Stroke rs3918226 7q36.1 NOS3 intronic T/C 0.0814 0.0263 (0.0223-0.0302) 1.05 (1.04-1.05) 3.44e-11
Stroke rs6991641 8p23.1 SOX7 intronic G/C 0.403 0.013 (0.0108-0.0152) 1.02 (1.02-1.03) 3.29e-09
Stroke rs1333049 9p21.3 CDKN2A intergenic C/G 0.481 0.0129 (0.0108-0.0151) 1.02 (1.02-1.03) 1.41e-09
Stroke 9:136138765 9q34.3 ABO intronic G/GC... 0.184 0.0155 (0.0128-0.0183) 1.03 (1.02-1.03) 2.05e-08
Stroke 11:46705193 11p11.2 ARHGAP1 intronic C/CT 0.28 0.0143 (0.0119-0.0167) 1.02 (1.02-1.03) 4.10e-09
Stroke rs59065675 15q26.1 FURIN intronic C.../C 0.47 0.0127 (0.0105-0.0149) 1.02 (1.02-1.03) 5.00e-09
Stroke rs814573 19q13.32 APOC1 intergenic T/A 0.188 0.0156 (0.0128-0.0184) 1.03 (1.02-1.03) 2.97e-08
Stroke 20:862958 20p12.3 PLCB1 intronic TA/T 0.76 0.0138 (0.0113-0.0164) 1.02 (1.02-1.03) 4.73e-08
IscStroke rs1894692 1q24.2 F5 intergenic G/A 0.0218 0.0546 (0.0478-0.0614) 1.1 (1.09-1.11) 8.22e-16
IscStroke rs369787256 4q25 PITX2 intergenic C/T 0.0905 0.0223 (0.0188-0.0257) 1.04 (1.03-1.05) 1.17e-10
IscStroke rs55730499 6q25.3 LPA intronic T/C 0.0817 0.0272 (0.0236-0.0307) 1.05 (1.04-1.05) 2.49e-14
IscStroke rs117733303 6q25.3 LPAL2 intronic G/A 0.0187 0.0428 (0.0356-0.05) 1.08 (1.06-1.09) 2.69e-09
99
IscStroke rs3918226 7q36.1 NOS3 intronic T/C 0.0814 0.0209 (0.0173-0.0246) 1.04 (1.03-1.04) 6.81e-09
IscStroke rs2205258 8q23.3 LOC107986968 intronic C/T 0.83 0.0151 (0.0125-0.0177) 1.03 (1.02-1.03) 6.76e-09
IscStroke rs8176719 9q34.2 ABO insertion TC/T 0.34 0.0145 (0.0124-0.0165) 1.02 (1.02-1.03) 2.17e-12
IscStroke rs1333049 9p21.3 CDKN2A intergenic C/G 0.481 0.0132 (0.0112-0.0151) 1.02 (1.02-1.03) 1.31e-11
IscStroke 11:46705193 11p11.2 ARHGAP1 intronic C/CT 0.28 0.0122 (0.01-0.0145) 1.02 (1.02-1.02) 3.22e-08
IscStroke rs814573 19q13.32 APOC1 intergenic T/A 0.188 0.0172 (0.0146-0.0198) 1.03 (1.02-1.03) 1.85e-11
IscStroke rs118068660 19p13.2 LDLR intergenic C/T 0.901 0.0193 (0.0159-0.0227) 1.03 (1.03-1.04) 1.43e-08
IscStroke rs12151925 20p12.2 FAT1P1 intergenic C/T 0.222 0.0129 (0.0105-0.0152) 1.02 (1.02-1.03) 4.26e-08
SAHStroke rs6025 1q24.2 F5 missense T/C 0.0231 0.0673 (0.0593-0.0753) 1.12 (1.11-1.14) 4.61e-17
SAHStroke rs36058710 9q34.2 ABO intronic CT/C 0.287 0.0166 (0.0139-0.0194) 1.03 (1.02-1.03) 1.03e-09
SAHStroke rs34850248 12q12 LINC02400 intergenic A/AC 0.0714 0.0268 (0.0221-0.0314) 1.05 (1.04-1.06) 9.95e-09
ICHStroke rs6025 1q24.2 F5 missense T/C 0.0231 0.0480 (0.0411-0.0549) 1.09 (1.07-1.1) 2.85e-12
ICHStroke rs11887534 2p21 ABCG8 missense G/C 0.935 0.0271 (0.0229-0.0313) 1.05 (1.04-1.06) 7.90e-11
ICHStroke rs372302634 3q22.3 ESYT3-MRAS intergenic T/T... 0.457 0.0121 (0.01-0.0142) 1.02 (1.02-1.02) 8.51e-09
ICHStroke rs6923947 6q22.32 LOC105377992 intergenic A/G 0.447 0.0127 (0.0106-0.0148) 1.02 (1.02-1.03) 9.5e-10
ICHStroke rs2077111 6q22.33 RPS4XP9 intergenic G/A 0.447 0.012 (0.00995-0.0141) 1.02 (1.02-1.02) 8.89e-09
ICHStroke rs1808593 7q36.1 NOS3 intronic G/T 0.25 0.0131 (0.0107-0.0155) 1.02 (1.02-1.03) 4.14e-08
ICHStroke rs7013277 8p23.1 XKR6 intronic C/A 0.396 0.0116 (0.00947-0.0137) 1.02 (1.02-1.02) 4.6e-08
ICHStroke 11:46705193 11p11.2 ARHGAP1 intronic C/CT 0.28 0.0133 (0.011-0.0156) 1.02 (1.02-1.03) 1.35e-08
Table 5.6: Genome-wide significant variants discovered by QTPhenProxy, EN Model, using
QC1 quality control. Cytogenic position was determined using [153]. rsID: variant id, Chr:
cytogenic position, Location: location of variant relative to the gene, Allele: risk/reference alleles,
RAF: risk allele frequency in population, Beta: Beta coefficient OR: Odds Ratio, 95% Confidence
Intervals
5.3.5 Conditional analysis refines candidate variants to mostly lead some nearby SNPs.
Conditional analysis of the GWAS with QC2 quality control for the QTPhenProxy EN model
for all stroke identified 7 candidate variants with genome-wide significance, all which are novel,
though some of the nearest genes to these loci have been identified in previous studies through
nearby loci. There were 3 loci identified for the stroke subtype ischemic stroke, 3 loci for sub-
arachnoid hemorrhage, and 3 loci for intracerebral hemorrhage (Table 5.7). Almost all of the
genome-wide significant variants overlapped with those found running the GWAS using QC1
quality control. New variants that were genome-wide significant for all stroke included a dele-
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tion variant that was intergenic to the gene ATP5MC1P3, an intronic variant of the MRSA gene,
and a 3’UTR variant in KCNJ4[152]. In addition, several genome-wide significant variants in the
MEGASTROKE stroke and ischemic stroke GWAS were near the variants that were genome-wide
significant in the QTPhenProxy EN GWAS. Almost all of those nearby MEGASTROKE genome-
wide significant variants replicated to at least nominal significance of 0.05 in the QTPhenProxy
EN GWAS (Table 5.8).
Phenotype rsID Chr. Gene P value MEGASTROKE P value
Stroke rs1894692 1q24.2 F5-SLC19A2 6.87E-10 0.435
Stroke rs8179838 2p21 MTA3 8.36E-06 0.515
Stroke rs769407520 3q22.3 ATP5MC1P3 2.50E-08 not found
Stroke rs6923947 6q22.32 LOC105377992 4.58E-07 0.04332
Stroke rs55730499 6q25.3 LPA 6.85E-10 0.05915
Stroke rs3918226 7q36.1 NOS3 6.45E-09 0.00134
Stroke 8:10206921 8p23.1 MSRA 4.62E-08 not found
Stroke rs1333049 9p21.3 CDKN2A-CDKN2B 5.02E-06 1.85E-07
Stroke 9:136138765 9q34.3 ABO 9.73E-09 not found
Stroke 11:46705193 11p11.2 ARHGAP1 7.06E-07 not found
Stroke rs59065675 15q26.1 FURIN 4.06E-07 not found
Stroke rs814573 19q13.32 APOC1-APOC1P1 2.52E-05 0.412
Stroke 20:862958 20p12.3 PLCB1 1.95E-06 not found
Stroke rs2269608 22q13.1 KCNJ4 4.23E-08 0.212
IscStroke rs1894692 1q24.2 F5-SLC19A2 1.90E-11 0.229
IscStroke rs369787256 4q25 PITX2-MIR297 3.69E-06 not found
IscStroke rs55730499 6q25.3 LPA 1.26E-09 0.0316
IscStroke rs117733303 6q25.3 LPAL2 0.000119 0.422
IscStroke rs3918226 7q36.1 NOS3 3.59E-06 0.00118
IscStroke rs2205258 8q23.3 LOC107986968 7.16E-06 0.415
IscStroke 9:1361387 9q34.2 ABO 4.99E-10 not found
IscStroke rs1333049 9p21.3 CDKN2A-CDKN2B 3.01E-06 1.09E-06
IscStroke 11:46705193 11p11.2 ARHGAP1 3.85E-05 not found
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IscStroke rs814573 19q13.32 APOC1-APOC1P1 2.20E-06 0.716
IscStroke rs118068660 19p13.2 LDLR 1.28E-06 1.14E-05
IscStroke rs12151925 20p12.2 LOC101929413-FAT1P1 0.000107 0.104
SAHStroke rs6025 1q24.2 F5 6.34E-18 0.453
SAHStroke rs36058710 9q34.2 ABO 1.59E-10 not found
SAHStroke rs34850248 12q12 LINC02400 7.18E-09 not found
ICHStroke rs6025 1q24.2 F5 1.52E-10 0.453
ICHStroke rs11887534 2p21 ABCG8 4.29E-08 6.85E-04
ICHStroke rs372302634 3q22.3 ESYT3-MRAS 4.03E-08 not found
ICHStroke rs6923947 6q22.32 LOC105377992 1.47E-07 0.00433
ICHStroke rs2077111 6q22.33 RPS4XP9 1.96E-06 0.0372
ICHStroke rs1808593 7q36.1 NOS3 2.96E-06 0.565
ICHStroke rs7013277 8p23.1 XKR6 2.06E-05 0.156
ICHStroke 11:46705193 11p11.2 ARHGAP1 3.59E-06 not found
Table 5.7: Genome-wide significant variants discovered by QTPhenProxy, EN Model, using
QC2 quality control. Also includes QC2 p-value for genome-wide significant variants from QC1
GWAS and p-values for variants from the MEGASTROKE stroke or ischemic stroke european
GWAS [11]. Cytogenic position was determined using [153]. rsID: variant id, Chr: cytogenic
position
5.3.6 Correlation between effect sizes of QTPhenProxy and traditional binary trait analysis
We determined the correlation between the effect sizes of the binary trait GWAS and QTPhen-
Proxy GWAS. Pearson correlation of the beta coefficients and log of the odds ratios increased when
restricting to variants with small p-values (max r2=0.70) (Figure 5.9). Too few variants, such as
with p-values > 5e-08 resulted in a decreased Pearson correlation.
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Phenotype Gene rsID QTPhenProxy p-value
Stroke LPA rs56393506 1.09E-08
Stroke NOS rs1799983 not found
Stroke CDKN2B-CDKN2A rs7859727 6.94E-05
Stroke ABO rs635634 1.07E-07
Stroke FURIN rs4932370 2.55E-05
Stroke COL4A1 rs9521634 0.00375
Stroke LOC105372798 rs720470 0.88
Ischemic stroke PITX2-MIR297 rs13143308 not found
Ischemic stroke LPA rs56393506 2.50E-09
Ischemic stroke NOS3 rs1799983 not found
Ischemic stroke CDKN2B-CDKN2A rs7859727 5.95E-05
Ischemic stroke ABO rs635634 7.93E-09
Ischemic stroke LDLR rs8103309 0.171
Subarachnoid Hemorrhage ABO rs635634 2.22E-06
Intracerebral Hemorrhage NOS3 rs1799983 not found
Table 5.8: QTPhenProxy EN Model GWAS using QC2 quality control P-value of variants
that were genome-wide significant in MEGASTROKE Stroke and Ischemic Stroke GWAS.
5.3.7 QTPhenProxy results for other diseases.
For myocardial infarction, traditional binary trait method recovered 487 variants while quanti-
tative trait linear regression using QTPhenProxy probabilities recovered 940 genome-wide signif-
icant SNPs and 2126 genome-wide significant hits using the EN and RF classifiers, respectively.
Out of the 487 variants determined by traditional methods, 204 variants overlapped in the EN QT-
PhenProxy linear regression. In contrast, for COPD, traditional binary trait method recovered 82
variants while QTPhenProxy method recovered 2544 and 2088 variants using RF and EN classi-
fiers, respectively. Out of the 82 variants determined by traditional method, none were recovered
using the QTPhenProxy method.
5.3.8 Specificity analysis of genome-wide significant variants using EBI-GWAS marker sets
From the over 2,000 EBI-GWAS disease variant marker sets mapped to organ systems, we cal-
culated the proportion of markers in each set that were found to be at genome-wide significance
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by our QTPhenProxy model with QC2 markers and principal components. We found that the or-
gan systems with markers sets with the highest proportion of genome-wide significant variants for
stroke included vascular disorders, investigations, psychiatric disorders, and general disorders and
administration site conditions (Figure 5.6). The enriched disease marker sets in the Investigations
class included the lab values lipoprotein A levels, lipoprotein a levels adjusted for apolipoprotein
A isoforms, blood protein levels, and white blood cell counts. The enriched disease marker sets in
the General disorders and administration site conditions included aortic valve stenosis and allergy,
while the Psychiatric disorders enriched marker sets were response to statins (LDL change) and ve-
nous thromboembolism. For ischemic stroke, the top enriched disease marker sets included those
described for stroke and also activated partial thromboplastin time, coagulation factor levels, pro-
tein biomarkers, soluble levels of adhesion molecules, pancreatic cancer, and urinary metabolites.
We also found GWAS results from diseases other than stroke to be enriched with corresponding
EBI-GWAS disease marker sets. QTPhenProxy EN and RF Model GWAS using QC1 quality
control showed increased proportion of significant variants for myocardial infarction (MI), COPD,
and Asthma in corresponding EBI-GWAS disease and System Organ Class marker sets compared
to all other marker sets, but not in Alzheimer’s or Parkinson’s disease. Representative plots (Figure
5.7 for MI, COPD, and Parkinson’s EN show increased median proportion significant variants in
disease and system organ class marker sets compared to other marker sets for MI and COPD but
not Parkinson’s disease. This difference is seen when the threshold for significance is 0.05 or
0.005.
5.3.9 LD score regression intercept, genomic inflation, and evaluation of genomic inflation
Using QC1 quality control, the genomic inflation for QTPhenProxy EN model for Stroke was
1.133, while using the QC2 quality control the genomic inflation for the same model was 1.134.
For binary traits using QC2 quality control, genomic inflation for stroke was 1.027. Using the
QTPhenProxy EN model with QC2 quality control, the genomic inflation for Ischemic stroke was
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Figure 5.6: Disease categories that are enriched for variants discovered by QTPhenProxy
genome-wide association study of Stroke. X-axis is the top percentile of marker sets in each
category, Y-axis is the proportion of variants in marker sets that overlap with QTPhenProxy
genome-wide significant variants. Each shape corresponds to a disease category. In color are
top disease categories: Square=Investigations, Triangle=Vascular disorders, Cross=Nervous sys-
tem disorders, X=General disorders and administration site conditions, Star=cardiac disorders, and
Diamond=Blood and lymphatic system disorders.
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Figure 5.7: Median proportion of significant variants stratified by disease, system organ class,
and other disease markers for QTPhenProxy EN model genome-wide association study of
MI, COPD, and Parkinson’s Disease with QC1 quality control. Colors correspond to negative
log10 of p-value significance threshold (-log10(alpha)). Panel A corresponds to Myocardial Infarc-
tion (MI) GWAS, Panel B, Chronic Obstructive Pulmonary Disease (COPD) GWAS, and Panel C,
Parkinson’s Disease. en= logistic regression model with elastic net penalty. First column of each
panel represents disease (dz) marker sets, second column, System Organ Class (sys) marker sets,
and third column other (oth) disease marker sets.
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Figure 5.8: Genomic Inflation within bins of variants with similar minor allele frequencies
for QTPhenProxy EN Model for Stroke with QC2 quality control. Orange line shows the
genomic inflation of each bin of variants, green line shows 1.0 genomic inflation, and blue bars
show numbers of SNPs (variants) in each bin, binned by log(MAF), or log(minor allele frequency.)
1.118, for subarachnoid hemorrhage was 1.122, and for intracerebral hemorrhage was 1.114. LD
score regression intercept for QTPhenProxy EN model with QC2 quality control for stroke was
1.037± 0.0088, for ischemic stroke, 1.031± 0.0077, for subarachnoid hemorrhage, 1.012± 0.008,
and for intracerebral hemorrhage, 1.051 ± 0.0081. We found that more common variants, or those
with higher minor allele frequencies, had higher genomic inflation than rarer variants (Figure 5.8).
5.3.10 Genetic Correlation of QTPhenProxy with MEGASTROKE and Coronary Artery Disease
GWAS
We measured a genetic correlation of 0.64 (p-value 1.8E-23) between the QTPhenProxy EN
Model for stroke, QC1 quality control, and the MEGASTROKE all stroke GWAS and a genetic
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Figure 5.9: Correlation between QTPhenProxy, EN Model GWAS and Binary trait GWAS
effect size. Pearson correlation is recorded in top right corner. From left to right, variants included
decreases by restricting p-value.
correlation of 0.60 (p-value 1.4E-19) between the QTPhenProxy EN Model for stroke, QC2 quality
control, and the MEGASTROKE all stroke GWAS. We also found a genetic correlation of -0.1 (p-
value 0.0065) between the MEGASTROKE all stroke GWAS and coronary artery disease GWAS,
and we found a genetic correlation of -0.0048 (p-value 0.88) between the QTPhenProxy EN Model
for stroke, QC1 quality control, and coronary artery disease GWAS.
5.3.11 Simulation of Conversion of Quantitative trait to Binary trait shows similar correlation of
effect sizes to empirical data.
We simulated the effect of a quantitative trait locus and nearby marker both on the original
quantitative trait and the binary trait converted from the quantitative trait using liability threshold-
ing. We found high correlation of effect sizes between the beta coefficients and log odds ratios of
the quantitative trait variants with p-value < 0.005 and their respective binary trait variant effect
sizes (Pearson correlation, r2=0.82) (Figure5.9). Lower p-values were not tested because of too
few qualifying variants. After standard normalizing the quantitative trait, we also found the slope
of its correlation with the log binary trait to be stable across the parameters, with a mean of 1.63
for each parameter except for marker allele frequency (1.35) and prevalence (1.77) (Figure 5.10).
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Figure 5.10: Slope of correlation between beta from simulated quantitative trait and log(odds
ratio) of simulated binary trait with varying simulation parameters. Left panels calculate
slope with all variants, right panels calculate slope with variants with p-value <0.005. (A) varies
the transformation of the probability distribution, where N(0,1) is a normal distribution with mean
0, variance 1, N(0,10) is a normal distribution with mean 0, variance 10, N(10,50) is a normal
distribution with mean 10, variance 50, norm is normalized by the maximum value, and orig is the
original distribution. (B) varies the prevalence of the trait, (C) varies the causal allele frequency,
(D) varies the recombination fraction between the causal allele and marker allele, and (E) varies
the marker minor allele frequency.
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5.4 Discussion
5.4.1 QTPhenProxy can identify patients with stroke using EHR data other than the disease di-
agnosis code
For all stroke and its subtype ischemic stroke, the machine learning models trained to assign
QTPhenProxy probabilities performed well (greater than 90% AUROC, greater than 30% maxi-
mum F1 score, 74-97% precision at 50). The models trained on subarachnoid hemorrhage and
intracerebral hemorrhage cases performed similarly with AUROC but with lower maximum F1
score and precision at 50. This may be due to the number of cases available for the two subtypes
to train on, which was an order of magnitude smaller ( 600 cases versus 3300-4300 cases). Impor-
tantly, we only trained on half of the cases and tested on the other half, which equates to 300-2200
cases, depending on the disease. From this small training set, we were able to assign a probability
of disease to all 500,000 subjects in the UK Biobank. This is a fraction of the over 40,000 cases
required to power the most recent genome-wide association study for stroke (MEGASTROKE).
5.4.2 QTPhenProxy discovers many new variants and recovers known disease variants to genome-
wide significance
Training on half the number of cases of each disease and assigning a probability from the
trained models to each UK Biobank subject resulted in 3-13 loci with genome-wide significance
using QTPhenProxy. In contrast, traditional binary trait GWAS using all disease cases resulted
in the discovery of 0 genome-wide significant loci for stroke, ischemic stroke, and subarachnoid
hemorrhage and 2 loci for intracerebral hemorrhage. In addition to new loci discovery, QTPhen-
Proxy recovered known disease variants to a significance level of 0.05 with a sensitivity better than
binary trait GWAS. In addition to recovering known variants, overall, the effect size of the known
variants in the binary trait GWAS was correlated with QTPhenProxy effect sizes for variants with
low p-values. These results suggest that the QTPhenProxy method can recover relevant variants
with fewer cases than traditional methods for stroke.
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5.4.3 Simulation of quantitative trait and corresponding binary trait further supported the corre-
lation of effect sizes between the two methods.
Our simulations showed high correlation between quantitative trait beta coefficients and binary
trait log odds ratio, which is similar to our empirical findings in the UK Biobank. We also show that
the correlation slope is relatively stable across all the different simulation parameters, suggesting
that there is a set correlation between quantitative traits and binary traits created from them. Further
simulation will need to determine the effects of multiple loci on correlation between quantitative
and corresponding binary traits.
5.4.4 Variants discovered for stroke are enriched in disease marker sets for vascular and neu-
rological disease, and variants discovered for other diseases were enriched for disease and
system specific markers.
As a specificity measure for the variants discovered by QTPhenProxy, we found the EN model
had the highest proportion of overlapping variants with EBI-GWAS marker sets related to vascular
disorders and associated lab values. QTPhenProxy variants improve the power of detecting vari-
ants related to diseases that are co-morbid or risk factors for stroke. We found that for myocardial
infarction, Asthma, and COPD, there were increased proportion of variants with a p-value signifi-
cance of 0.05 or lower for disease marker sets corresponding to the related disease or system organ
class compared to other disease marker sets. This was not the case for Alzheimer’s and Parkin-
son’s disease. This suggests that for some diseases, the variants discovered by QTPhenProxy were
specific for the study disease and its system.
5.4.5 QTPhenProxy has high genetic correlation with the MEGASTROKE GWAS
We found high genetic correlation (0.60-0.64) between the MEGASTROKE all stroke GWAS
and QTPhenProxy EN Model stroke GWAS. In addition, we found little genetic correlation(-
0.1 and -0.0048 respectively) between the MEGASTROKE and a recent coronary artery disease
(CAD) GWAS ([159]) and QTPhenProxy and the same CAD GWAS. The same genetic correlation
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calculation between MEGASTROKE and CAD was reported in [11] as a large genetic correlation
of around 0.5 with a p-value of 1E-20; therefore, further work will be needed to resolve this dis-
crepancy. The high genetic correlation between MEGASTROKE and QTPhenProxy suggests that
both studies highlight shared genetic underpinnings and predicts that risk factors for stroke GWAS
should have positive genetic correlation with QTPhenProxy as it has for MEGASTROKE GWAS
in the past. [11].
5.4.6 Low LD score regression intercepts relative to genomic inflation suggests high polygenicity
Our genome-wide association studies using QTPhenProxy had moderate genomic inflation,
slightly above 1.1, but low LD score regression intercepts near 1.0. The corresponding binary
trait GWAS had genomic inflation below 1.05, suggesting minimal population stratification. Since
the population for the binary trait GWAS was the same as that used for QTPhenProxy, this sug-
gests that polygenicity, rather than population stratification, is the cause for genomic inflation.
Polygenicity, or the contribution of small effects of many genes to a phenotype, may be the more
likely cause[157]. In addition, Bulik-Sullivan et. al. argue that genomic inflation can increase
with sample size when there is polygenicity, and LD score regression intercept is more robust in
distinguishing inflated p-values from polygenicity. As seen in [161], increased genomic inflation
with common variants over rare variants suggests polygenicity. We show a similar upward trend
in Figure 5.8. Another sign of true signal over inflated signal is the evidence of causal variants in
linkage disequilibrium, as seen in a Manhattan or Hudson plot [161]. Figures figs. 5.3 and 5.4 show
genome-wide significant variants in linkage disequilibrium with each other. Finally, this study re-
ports results from using two different quality controls in the genome-wide association analysis,
QC1, and more stringent, QC2. Results using QC1 showed more variants with genome-wide sig-
nificance and discovered more new variants for stroke than the QC2 GWAS. This may lead one
to believe that more stringent quality control led to reduced inflation of p-values. However, the
genomic inflation of the p-values from the QC1 GWAS was the same as the genomic inflation of
the p-values from the QC2 GWAS (1.134 vs 1.133), with the QC2 GWAS having a slightly higher
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LD score regression intercept value (1.0288 vs 1.0369). This suggests that the p-values from the
QC1 GWAS may not be overly inflated.
5.4.7 QTPhenProxy replicates known stroke variants and discovers variants within cardiovascu-
lar disease genes
Several of the genes discovered by the QTPhenProxy GWAS, using QC1 or QC2 quality con-
trol have been associated with stroke, including NOS3, FURIN, PITX2, CDK2NB, LDLR, and
ABO[11, 162]. NOS3, in particular, was discovered through meta-analysis of the MEGASTROKE
results with the UK Biobank[162]. We were able to replicate this association using only the QT-
PhenProxy method on the UK Biobank, and not traditional binary trait analysis. NOS3 has been
shown to be related to hypertension either through salt excretion regulation in the kidney[163] or
regulation of vascular relaxation in endothelial cells[164]. Other discovered genes by QTPhen-
Proxy are also associated with related cardiovascular diseases. The F5 gene codes for an essential
coagulation factor and mutations that can lead to increased thrombosis or hemorrhage, depending
on the mutation[165, 166, 167]. LPA (Lipoprotein-A) codes for a protein that can contribute to
atherosclerosis[168, 169]. Mutations in the PLCB1 gene, which encodes for phospholipase syn-
thesis, have been found in epilepsy and seizures[170]. The LDLR gene codes for the low-density
lipoprotein receptor, which is involved in cholesterol production[171], and the APOC1/APOC1P1
genes code for parts of apoliprotein C1, which are involved in high density lipoprotein metabolism
[172]. ARHGAP1, a gene coding for Rho GTPase activating protein 1 has been associated with can-
cer phenotypes and activation of hypoxic and inflammatory pathways[173, 174, 175]. The ABCG8
gene has been associated with combined gwas of lipids and inflammation, lipid levels, and gall-
stone disease[176]. EYST3 and XKR6 gene mutations have been associated with coronary artery
disease and ischemic stroke respectively in Asian populations, and MRAS gene mutations have
been associated with coronary artery disease in two populations[177, 178, 179, 180]. These results
suggest that QTPhenProxy has replicated genome-wide significant mutations in genes known to be
related with stroke and discovered those associated with related risk factors such as coronary artery
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neurological diseases. Out of the 13 newly discovered variants with genome-wide significance, five
are intronic or in nearby genes that have been found in previous studies (MEGASTROKE), and
five more have been discovered in previous GWAS studies of related cardiovascular diseases. The
variants within and near the F5 gene had the highest genetic signal for stroke and all of its sub-
types, even though it was not replicated in the MEGASTROKE GWAS. Out of all the new variants
discovered by the QTPhenProxy EN model using the GWAS QC2 quality control, the rs11887534
variant, a missense mutation within the ABCG8 gene, replicated to a p-value significance of 6.85E-
04 in the MEGASTROKE stroke GWAS of over 40,000 European ancestry subjects. Using a tenth
of the number of cases, QTPhenProxy discovered a variant within a new gene that replicated in
MEGASTROKE, and discovered variants within known stroke genes.
5.4.8 Limitations
There are several limitations with this method. First, out of the five machine learning models
used in QTPhenProxy, only two provided probabilities along a continuous scale. Adaboost, gra-
dient boosting, and logistic regression using L1 penalty models, although with high performance,
assigned probabilities in discrete bins. These distributions violate the genome-wide association
linear regression assumption of normal distribution of the quantitative trait. Although the prob-
abilities produced by EN and RF models were not initially normally distributed, they were con-
tinuous, and could be adjusted with quantile normalization. In addition, the GWAS results from
QTPhenProxy using the RF model resulted in many more hits than the EN model, and reduced
sensitivity to known disease variants. Further study will be required to understand why one model
gave more sensitive and specific results than the other, and whether there was p-value inflation in
the random forest models. In addition, from our preliminary studies, the sensitivity of recovering
known loci for diseases other than stroke and ischemic stroke did not improve using QTPhenProxy.
This may be because the training model for phenotyping patients was optimized for stroke[112].
Since stroke is an acute event than can be identified with high accuracy in the electronic health
record, this method may not translate as well to other diseases, such as chronic illnesses. Another
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potential limitation of the study is that only about half of known loci for stroke are replicated with
significance of less than 0.05 in the QTPhenProxy method, even though new variants are suggested.
5.4.9 Conclusions
We have developed a method, QTPhenProxy, that we have shown improves the power of
genome-wide association studies in stroke and three of its subtypes: ischemic stroke, subarachnoid
hemorrhage, and intracerebral hemorrhage with an order of magnitude fewer cases than required
for traditional genome-wide association studies of the same diseases. Converting dichotomous
traits to quantitative ones could result in improvement of power by incorporating electronic health
record information for subjects who may have genetic susceptibility to stroke but may not have
experienced a stroke yet. Previous studies have shown that for diseases with low prevalence, there
can be a reduction of power using logistic regression for binary trait GWAS compared to linear
regression for quantitative trait GWAS[19]. Recently, [12] showed that the inclusion of ischemic
stroke risk factors’ genome-wide significant SNPs in polygenic risk score improves prediction of
ischemic stroke. This supports our idea that inclusion of risk factor information into the phe-
notype can help detect genetically susceptible subjects. We plan to test the correlation between
our QTPhenProxy probabilities with the metaGRS polygeneic risk scores from [12] in the UK
Biobank. We have shown that there is high genetic correlation between MEGASTROKE and QT-
PhenProxy. We also show that with as few as 2200 stroke subjects we can recover known variants
of stroke and discover new variants that have been linked to cardiovascular and nervous system
diseases. This method could be useful for studies with a small set of cases and without access to
large meta-analyses. We also have suggested new variants that warrant further replication in other
groups. QTPhenProxy shows the benefits of incorporating electronic health record data to convert
traditional binary traits to quantitative in improving GWAS power.
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Conclusion
Stroke is a highly heterogeneous and heritable disease that is a leading cause of mortality and
disability. The etiology of strokes are varied and complex, caused by a combination of modifiable,
such as lifestyle, and non-modifiable, such as genetics, risk factors and environmental influences.
Elucidating the genetics of stroke and related diseases, such as coronary artery disease, has led to
a better understanding of the genetics of the disease and potential avenues for treatment[181, 162,
11]. For stroke, however, large scale genome-wide association studies have discovered far fewer
variants than related risk factors such as blood pressure and atrial fibrillation[12]. Past studies
have suggested that this is due to the phenotypic heterogeneity of stroke[8, 11]. Recent studies in
polygenic risk scores of stroke have also found improved predictive power of stroke patients when
incorporating known variants of risk factors for stroke. This suggests that there are variants still to
be discovered for stroke, and they most likely overlap with related diseases. In an era of large scale
biobanks paired with electronic health record data, we hypothesized that a high-throughput method
of incorporating medical information of stroke patients into a phenotypic score could bolster the
power of genomic studies.
In this thesis, we combined supervised machine learning with large scale EHR and biobank
databases to develop a high-throughput phenotyping method that improves the power of stroke
genome-wide association studies. In Chapter 2, we develop this high-throughput phenotyping
method, and find, across several supervised machine learning phenotyping models trained on a
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small cohort of cases and controls, high performance of acute ischemic stroke (AIS) case identifi-
cation with minimal feature processing. We built upon previous stroke machine learning phenotyp-
ing algorithms by using a data agnostic approach to identify features such as diagnostic procedure
codes that could be included to identify stroke patients. In our external validation of the method
in the UK Biobank, we also found that the top probabilities from a model-predicted AIS cohort
were significantly enriched for AIS patients without AIS diagnosis codes. Our findings support
machine learning algorithms as a generalizable way to accurately identify AIS patients without
using process-intensive manual feature curation. In chapter 3, we applied factorization methods
to subtype acute ischemic stroke patients, a potential avenue to reduce phenotypic heterogenity
in stroke. We found non-negative matrix factorization to produce more stable subtypes over hi-
erarchical Poisson factorization, and we found several subtypes significantly correlated to stroke
severity. These subtypes highlighted known risk factors for stroke, including atrial fibrillation,
diabetes mellitus, and acute respiratory failure. We then tested whether the probabilities gener-
ated from our supervised machine learning phenotyping models, which we called QTPhenProxy,
could be used as phenotypic scores for genetic studies. This required the use of the phenotypic
score as a quantitative trait. In Chapter 4, we showed that some of our high performing QT-
PhenProxy models estimated the heritability of AIS within the range of literature values and oth-
ers underestimated AIS heritability, while traditional case/control assignment of AIS was unable
to estimate AIS heritability. Our venous thromboembolism genome-wide association study was
under-powered to show whether converting a phenotype from a binary to quantitative trait could
improve the power of genome-wide association studies. In Chapter 5, however, in the UK Biobank
database, we showed that QTPhenProxy can discover genome-wide significant variants associated
with stroke with an order of magnitude fewer cases (4,354) than the most recent stroke GWAS,
MEGASTROKE (40,585). We found up to 7 LD independent loci that pass genome-wide signif-
icance while the binary definition yielded no genome-wide significant hits. The majority of the
discovered variants were near genes known to be associated with stroke. In addition, we found a
novel locus in the ABCG8 gene that replicates in MEGASTROKE. We introduced a method that
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may improve the power of genome-wide association studies when limited curated cohort data are
available within a healthcare system.
This thesis also lays the groundwork for future studies along several avenues. Although we
began to understand what the probabilities assigned from the phenotyping models mean through
calibration and performance, further study is warranted through validation of the models by physi-
cians. In addition, although we used supervised machine learning models for ease of reproducibil-
ity and implementation, incorporation of timeline, natural language processing of notes, and appli-
cation of deep learning models could improve performance of the models. A future exploration for
subtyping stroke would determine whether the subtypes found have reduced phenotypic hetero-
geneity compared to traditional subtypes of stroke, and thus lead to reduced genetic heterogeneity
and clearer genetic signal. A first step would expand the subtyping cohort to all stroke patients in
the electronic health record and estimate the heritability using RIFEHR and SOLARstrap[51]. In
addition, we could compare other subtyping methods such as topological data analysis and deep
learning methods such as denoising autoencoders to the factorization methods to determine the
best method for subtyping stroke.
We would like to generalize QTPhenProxy for more diseases. Many diseases, such as en-
dometrosis or autoimmune diseases, are undiagnosed or misdiagnosed, and may benefit from a
supervised machine learning algorithm trained on EHR data to identify potential patients[182, 88,
183, 184] and improve the power of their genetic studies. To start, we need to further explore
why QTPhenProxy did not improve the power of other disease GWAS in the UK Biobank. This
would include determining which aspects of the model are most informative, whether it be the
effect size or penetrance of the variant, the phenotypic heterogeneity of the disease, the duration
of the disease, the performance of the model, or the the number of cases available. In addition,
polygenic risk scores are an important recent addition to the genomics field, and recently have been
successfully applied to stroke[12]. The score is comprised of the effect sizes of variants known to
be associated with the study disease through GWAS[185]. An important future direction of this
thesis would be to determine the correlation between the polygenic risk score of stroke with the
119
phenotypic probabilities assigned by QTPhenProxy in the UK Biobank. This would suggest that
the incorporation of EHR information into the trait plays a similar role to incorporating variants
from risk factors, as shown in [12].
There is still a long way to go to fully identify the genetic burden of stroke. Increased cohort
size to improve power and disease subtypes to reduce phenotypic heterogeneity are established
methods for identifying variants. To keep up with the hundreds of thousands of future subjects,
automated methods of cohort and subtype identification are needed. In addition, new methods to
improve genomic power, such as considering traditional binary traits as quantitative by utilizing
a phenotypic score, should be further explored and expanded upon. This thesis demonstrates the
promise of incorporating large but messy sets of data, such as the electronic health record, to
improve signal in genome-wide association studies.
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